Some Statistical Learning Methods for Procuring Individualized Treatment Rules in Personalized Healthcare by Zhou, Yiwang
Some Statistical Learning Methods for Procuring




A dissertation submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
(Biostatistics)
in The University of Michigan
2021
Doctoral Committee:
Professor Peter X.K. Song, Chair
Professor Karen E. Peterson





© Yiwang Zhou 2021
ACKNOWLEDGEMENTS
Throughout the writing of this dissertation, I have received a great deal of support
and assistance from my supervisor, committee members, collaborators, as well as my
families and friends.
I would first like to thank my supervisor, Professor Peter Song, who provides me
with a lot of guidance and advice for my dissertation research. His expertise and
insights in biostatistical research help me greatly in the formulation of my research
questions and the development of my methodologies in the field of personalized health-
care. I will always remember the time talking with him about my research progress
and the manuscripts revised by him with full of comments. His passion for scien-
tific research inspires me to start a career in academia. I hope that I can become a
successful researcher like him in the future.
I would also like to acknowledge my dissertation committee, including Professor
Karen Peterson, Professor Min Zhang, and Assistant Professor Zhenke Wu, for their
advice and suggestions on my dissertation research. Specifically, I want to thank
Karen for providing me with the calcium supplementation trial data as a real data
application in my second and third chapters. Her inputs of the background knowl-
edge in nutritional sciences help me understand the data better for the derivation of
individualized treatment rules in precision nutrition.
My dissertation research has been motivated and benefited significantly from sev-
eral collaborative projects. I want to thank Dr. Haoda Fu from Eli Lilly for providing
me with the diabetes clinical trial data for illustrating the performance of my pro-
ii
posed method in Chapter II. I am grateful to Professor Ivo Dinov for giving me
guidance and advice on a project studying the neuroimaging biomarkers in the UK
Biobank. Finally, I am thankful to the whole ELEMENT DMMC group for sharing
ideas and discussions on data analyses for the ELEMENT cohort study. All these
experiences serve as the foundation for me to make progress step by step and will
continue to nourish me until I grow up as an independent researcher in biostatistics.
Last but not least, I want to express my sincerest gratitude to my families and
friends. Thanks to my parents, Yongyuan Zhou and Huiyu Lu, for supporting me
throughout this entire time of Ph.D. study. Their support is my greatest encourage-
ment on the journey of knowledge pursuing. Thanks to my husband, Jiyuan Yang, for
always standing by my side when I need him and for giving me plenty of space when I
want to be alone. His endless love, support, and understanding make me realize that
I always have a harbor to rely on. Thanks to Ming Tang, Yingchao Zhong, Sai Chen,
Huayun Hou, Lu Xia, and all my other friends for supporting me through the darkest
time in my life so far. Thanks all friends for taking care of me and accompanying me.




ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . ii
LIST OF FIGURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vi
LIST OF TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . viii
LIST OF APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . xi
ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xii
CHAPTER
I. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
II. Net Benefit Index: Assessing the Influence of a Biomarker
for Individualized Treatment Rules . . . . . . . . . . . . . . . . 7
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.2 Application: A Diabetes Clinical Trial . . . . . . . . . . . . . 10
2.3 Formulation . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
2.3.1 Outcome Weighted Learning and Optimal ITR . . . 12
2.3.2 Treatment Reallocation . . . . . . . . . . . . . . . . 13
2.3.3 Net Benefit Index (NBI) . . . . . . . . . . . . . . . 15
2.3.4 Test for Significant NBI . . . . . . . . . . . . . . . . 16
2.4 Simulation Experiments . . . . . . . . . . . . . . . . . . . . . 18
2.4.1 Single-variable-based Decision Rule Evaluation . . . 19
2.4.2 Multiple-variable-based Decision Rule Evaluation . . 20
2.5 Analysis of Diabetes Trial Data . . . . . . . . . . . . . . . . . 22
2.6 Concluding Remarks . . . . . . . . . . . . . . . . . . . . . . . 27
III. Synergistic Self-Learning Approach to Establishing Individ-
ualized Treatment Rules from Multiple Benefit Outcomes . . 30
iv
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
3.2 Application: Calcium Supplementation Trial . . . . . . . . . 34
3.3 Formulation of SS-learning . . . . . . . . . . . . . . . . . . . 37
3.3.1 Basic Setting . . . . . . . . . . . . . . . . . . . . . . 37
3.3.2 Synergistic Self-learning . . . . . . . . . . . . . . . . 37
3.3.3 Algorithmic Convergence . . . . . . . . . . . . . . . 41
3.3.4 Tuning Parameter Selection . . . . . . . . . . . . . 41
3.4 Simulation Experiments . . . . . . . . . . . . . . . . . . . . . 42
3.5 Analysis of Calcium Supplementation Trial . . . . . . . . . . 45
3.6 Concluding Remarks . . . . . . . . . . . . . . . . . . . . . . . 52
IV. Longitudinal Self-Learning of Individualized Treatment Rules
with Missing Data . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
4.2 Application: Longitudinal Calcium Supplementation Trial . . 57
4.3 Formulation of LS-learning . . . . . . . . . . . . . . . . . . . 60
4.3.1 Notation . . . . . . . . . . . . . . . . . . . . . . . . 60
4.3.2 Longitudinal Self-learning . . . . . . . . . . . . . . . 61
4.3.3 Scaled Tuning Scheme . . . . . . . . . . . . . . . . . 63
4.4 Simulation Experiment . . . . . . . . . . . . . . . . . . . . . 65
4.4.1 Simulation Setting . . . . . . . . . . . . . . . . . . . 65
4.4.2 Simulation Results . . . . . . . . . . . . . . . . . . 67
4.5 Derivation of ITR for Longitudinal Calcium Trial . . . . . . . 69
4.6 Concluding Remarks . . . . . . . . . . . . . . . . . . . . . . . 74
V. Summary and Future Work . . . . . . . . . . . . . . . . . . . . . 76
APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80




2.1 (a) Effects of pioglitazone and gliclazide on reducing fasting plasma
glucose (FPG) during the 52-week period. (b) Average reduction rate
of FPG by pioglitazone and gliclazide in the 52-week period. . . . . 11
2.2 Changes of the subjects included in the calculation of V (D) when new
biomarker X2 is included in the estimation of the decision function.
Sizes of the circles and triangles reflect the magnitude of the clinical
benefit B. Black circles and triangles are the subjects included in the
calculation of V (D) since they have D(X) = A. Subjects in group
“gain” and “loss” are pointed by arrows. (a) Decision function f(X1)
estimated only on the existing biomarker X1. (b) Decision function
f(X1, X2) estimated on X1 and X2. . . . . . . . . . . . . . . . . . . 14
3.1 Mechanistic pathway of fetal exposure to lead. During pregnancy, the
increasing maternal bone turnover results in an elevated lead release
into plasma, which causes the increasing lead concentrations in cord
blood and breast milk. Such maternal lead exposure together with
environmental lead exposure result in an overall detrimental effect on
the neurobehavioral and cognitive development of infants. . . . . . 36
3.2 Workflow of the proposed synergistic self-learning algorithm. . . . . 40
3.3 Comparison of prediction accuracy on the training and validation
datasets by different methods under (a) varying β3, (b) varying σ3,
(c) varying n1/n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
3.4 Evaluation of predictor balance. (a) Distributional balance of propen-
sity score before and after weighting. (b) predictor balance before and
after weighting illustrated by the absolute standardized mean differ-
ences. The thresholds -0.1 and 0.1 are shown as the vertical dashed
lines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
vi
4.1 Missing of PBC values at different visit times. (a) Percentage of
missing and observed PBC values at month 3, 6, 12, 18, 24, 30,
and 36. (b) Stratification of mother-child pairs into different missing
patterns based on individual endpoints. . . . . . . . . . . . . . . . 58
4.2 Trajectories of PBC values in the calcium supplementation and placebo
group. The black summary line is fitted by the generalized additive
model (GAM). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
4.3 Change of tuning parameter λj according to standardized time t̃j. . 65
4.4 (a) Distributional balance of the propensity scores before and af-
ter weighting. (b) Balance of individual predictor before and after
weighting adjusted by ASMD under threshold 0.1, indicated by the
dashed lines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
F.1 Convergence analysis under (a) varying β3, (b) varying σ3, and (c)
varying n1/n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
G.1 Comparison of prediction accuracy on the training and validation
datasets by different methods with single low-quality dataset using
parameter tuning based on GAM under (a) varying β2, (b) varying
σ2, (c) varying n1/n. . . . . . . . . . . . . . . . . . . . . . . . . . . 101
G.2 Comparison of prediction accuracy on the training and validation
datasets by different methods with single low-quality dataset using
parameter tuning based on linear regression under (a) varying β2, (b)




2.1 Discovery rates for X3 and X4 in the single-variable-based decision
rule evaluation. (Discovery rate for X4 equals 1-specificity.) . . . . 20
2.2 NBI values for X3 and X4 in the single-variable-based decision rule
evaluation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.3 Size, TDR, MCC, and CCR for variable selection based on NBI test,
SAS and riskRFE in the multiple-variable-based decision rule evalu-
ation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
3.1 Summary statistics of the predictors in the calcium supplementation
trial. Mean (sd) and percentage values are shown, where p-values are
obtained from t-test and chi-square test for the numeric and categor-
ical variables, respectively. . . . . . . . . . . . . . . . . . . . . . . . 36
3.2 Selected weighting values λ2 and λ3 (mean (sd)) based on SS-learning
using proposed tuning. . . . . . . . . . . . . . . . . . . . . . . . . . 45
3.3 Estimated value function of B1 (mean (sd)) based on SS-learning
with proposed tuning, SS-learning with oracle tuning, OWL on S1,
and OWL on S = S1 ∪ S2 ∪ S3. . . . . . . . . . . . . . . . . . . . . 46
3.4 Estimated value function of B2 (mean (sd)) based on SS-learning
with proposed tuning, SS-learning with oracle tuning, OWL on S1,
and OWL on S = S1 ∪ S2 ∪ S3. . . . . . . . . . . . . . . . . . . . . 46
3.5 Estimated value function of B3 (mean (sd)) based on SS-learning
with proposed tuning, SS-learning with oracle tuning, OWL on S1,
and OWL on S = S1 ∪ S2 ∪ S3. . . . . . . . . . . . . . . . . . . . . 47
3.6 Treatment assignment comparison between complete randomization
and f̂3 estimated by SS-learning. . . . . . . . . . . . . . . . . . . . 50
viii
3.7 Estimated value functions of B1, B2 and B3 based on A, the estimated
ITR f̂1, f̂2, f̂3 for the analysis of the calcium supplementation trial. 50
3.8 Summary statistics of the predictors based on treatment allocation
according to f̂3. Mean (sd) and percentage values are shown for the
numeric and categorical predictors respectively. p-values are obtained
from t-test and chi-aquare test. . . . . . . . . . . . . . . . . . . . . 51
4.1 Summary statistics of the predictors included in ITR derivation.
Mean (sd) and percentage are shown, where p-values are obtained
from t-test and chi-square test for numeric and categorical variables,
respectively. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
4.2 Average prediction accuracy (mean (sd)) on both training and vali-
dation datasets among the five methods to derive ITR. . . . . . . . 68
4.3 Estimated value functions evaluated as B1 to B5 on the training data
S for five methods of ITR derivation. . . . . . . . . . . . . . . . . 68
4.4 Estimated intercepts and coefficients of the predictors in the esti-
mated ITRs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
4.5 Treatment assignment comparison between complete randomization
and f̂4 estimated by LS-learning. . . . . . . . . . . . . . . . . . . . 72
4.6 Estimated value functions at each visit and the average based on the
estimated ITR f̂1, f̂2, f̂3 and f̂4 derived in the calcium supplementa-
tion trial. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
4.7 Summary statistics of the predictors based on treatment allocation
according to f̂4. Mean (sd) and percentage values are shown, where
p-values are obtained from Wilcoxon rank-sum test and chi-aquare
test for numeric and categorical variables, respectively. . . . . . . . 74
C.1 Size, TDR, MCC, and CCR for variable selection based on NBI test,
SAS, and riskRFE in the multiple-variable-based decision rule eval-
uation when Xe = Null. . . . . . . . . . . . . . . . . . . . . . . . . 86
D.1 Size, TDR, MCC, and CCR for variable selection based on NBI test,
SAS and riskRFE in the multiple-variable-based decision rule evalu-
ation when n = 200. . . . . . . . . . . . . . . . . . . . . . . . . . . 88
ix
D.2 Size, TDR, MCC, and CCR for variable selection based on NBI test,
SAS and riskRFE in the multiple-variable-based decision rule evalu-
ation when SVM is performed under Gaussian kernel. . . . . . . . 89
D.3 Prediction accuracy for ITRs derived by NBI and the standard OWL
in the multiple-variable-based decision rule evaluation. . . . . . . . . 89
D.4 Size, TDR, MCC and CCR in the multiple-variable-based decision
rule evaluation based on l1-OWL when Xe = Null. . . . . . . . . . 90
D.5 Discovery rates for X3 and X4 in the single-variable-based decision
rule evaluation for the additional nonlinear setting. (Discovery rate
for X4 equals 1-specificity.) . . . . . . . . . . . . . . . . . . . . . . 90
D.6 NBI values for X3 and X4 in the single-variable-based decision rule
evaluation for the additional nonlinear decision rule. . . . . . . . . 90
D.7 Size, TDR, MCC, and CCR for variable selection based on NBI test,
SAS and riskRFE in the multiple-variable-based decision rule evalu-
ation for the additional nonlinear decision rule. . . . . . . . . . . . 91
F.1 SSE (mean (sd)) based on SS-learning with proposed tuning, SS-
learning with oracle tuning, OWL on S1, and OWL on S = S1∪S2∪
S3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
F.2 Computation time in second (mean (sd)) based on SS-learning with
proposed tuning, OWL on S1, and OWL on S = S1 ∪ S2 ∪ S3. . . . 96
G.1 Selected weighting values λ2 (mean (sd)) based on SS-learning us-
ing the proposed tuning method by linear regression and GAM with




A. Outcome Weighted Learning (OWL) . . . . . . . . . . . . . . . . . . . 81
B. Support Vector Machine (SVM) solution to OWL . . . . . . . . . . . 83
C. Multiple-variable-based ITR Derivation when Xe = Null for Chapter II 85
D. Additional Simulation Experiments for Chapter II . . . . . . . . . . . 87
E. Proof of Algorithm III.1 for Chapter III . . . . . . . . . . . . . . . . . 92
F. Additional Simulation Results for Chapter III . . . . . . . . . . . . . . 95
G. Nonlinear Simulation Experiment for Chapter III . . . . . . . . . . . . 98
xi
ABSTRACT
Precision health has gained increasing attention in recent years to deliver indi-
vidualized healthcare to patients. One central task of precision health is to establish
individualized treatment rules (ITRs) for patients through their heterogeneous re-
sponses in that tailored interventions are undertaken to maximize therapeutic effects.
Although various methods have been proposed to estimate optimal ITRs, specific
methodological challenges remain to be addressed, such as validating an existing
ITR, procuring an ITR with multiple views and missing clinical data. In this dis-
sertation, we develop new statistical learning methods to extend and improve the
current methodologies used to derive ITRs.
Chapter II focuses on a task of clinical importance: utilizing novel candidate
biomarkers to update an existing ITR to improve clinical benefits. I propose a new
statistical framework, termed net benefit index (NBI), to quantify added values of
candidate biomarkers when they are included in an existing ITR. NBI works by assess-
ing a contrast between the resulting gain-and-loss of benefits when a biomarker enters
an ITR to reallocate patients in treatments. To account for sampling uncertainty in
gauging the contribution of a biomarker, I propose an NBI-based test statistic whose
empirical null distribution is constructed by treatment-stratified permutation. I ap-
ply this NBI method to a randomized clinical trial on patients with type 2 diabetes
to select useful biomarkers to improve an existing ITR for assigning pioglitazone or
gliclazide to diabetic patients. As a result, the updated ITR helps maximally reduce
xii
fasting plasma glucose concentration over the 52 weeks of treatment.
Chapter III concerns the development of a multi-view statistical learning approach
to procuring ITR for precision nutrition, in the hope to maximize benefits of subjects
taking nutritional supplementations. A key issue pertains to the availability of multi-
ple endpoints for health benefits with different degrees of clinical relevance. I propose
a new statistical learning method, termed synergistic self-learning (SS-learning), to
address two major methodological challenges in ITR derivation, including heteroge-
neous multivariate outcomes and complex missing data patterns. I show both the-
oretically and numerically that SS-learning can effectively synergize heterogeneous
benefit variables from multiple training data sources. I apply SS-learning to a cal-
cium supplementation trial and identify several important predictors critical in ITR
estimation. The resulting ITR would lead to a higher expected reduction in prenatal
lead exposure, measured by infant blood lead concentration at birth, should it be
implemented to pregnant women in the population.
Motivated from the calcium supplementation trial, Chapter IV centers at a further
extension of SS-learning to longitudinal self-learning (LS-learning), through which I
aim to establish an effective ITR using longitudinal benefit outcomes. The endpoint of
the trial is child’s blood lead concentration at age of 3 years old, so the resulting ITR
can guide pregnant women for their daily calcium intake to maximize the long-term
reduction of lead exposure by their children. I propose a temporally weighted self-
learning paradigm in LS-learning, which enables to synergize auto-correlated training
data sources with repeated measurements. I also develop a new tuning procedure
by introducing a scaled tuning method, in which tuning parameters are governed by
a certain function of observational time. Applying LS-learning to the calcium sup-
plement trial, we establish an ITR from longitudinal benefit outcomes that contains
several important predictors to reduce child’s long-term lead exposure at age 3 should




Precision health, including topics of individualized medicine and individualized
diet, has received increasing attention in recent years (Council et al., 2011; Collins
and Varmus , 2015). Instead of a one-drug-fits-all paradigm, precision health is an
innovative framework, in which healthcare is customized with personal-level medical
decisions, treatments, practices, and products. It proposes tailored medical practice
to a subgroup of patients by individualized rules that take into account individ-
ual variability, for example, genes, environment, and lifestyle (Yau, 2019; Niculescu
et al., 2019; Lu et al., 2014; Jones et al., 2019). One major objective of personalized
healthcare is to maximize therapeutic benefits for patients, who may experience het-
erogeneous responses to different types of treatments, by assigning them to a “right”
treatment instead of the one based on the average treatment benefit for the entire
target population.
One central analytic task in precision health is to establish individualized treat-
ment rules (ITRs) that enable us to guide the assignment of treatments to individual
patients according to their personal characteristics. Various approaches have been
proposed in the literature to construct ITRs, including Q-learning (Watkins , 1989),
A-learning (Murphy , 2003), outcome weighted learning (OWL) (Zhao et al., 2012),
residual weighted learning (RWL) (Zhou et al., 2017), just to name a few. Q-learning
1
and A-learning have been shown to estimate the optimal ITR effectively under cor-
rectly specified regression models. However, both these approaches fail to give stable
results when the regression model used for ITR derivation is misspecified. This short-
coming is rooted in the fact that a regression-based method focuses on the prediction
of benefit outcomes, which is not the direct solution to the derivation of ITR in preci-
sion medicine, which aims at maximizing the expected benefits of interest (Murphy ,
2005). In order to derive ITRs under the real goal of precision medicine, different
methodologies that directly optimize the population-level expected outcomes have
been proposed. Zhao et al. (2012) proposes OWL and shows that estimating the
optimal ITR is equivalent to a classification problem of treatment groups, in which
subjects in different groups are weighted proportionally to their observed clinical
benefits. In OWL, support vector machine (SVM) is invoked to estimate the optimal
ITR. Later, (Zhou et al., 2017) proposes RWL, which shows to be able to improve
the finite sample performance of OWL by weighting individual subjects with their
residuals obtained by a regression fit of benefit outcomes on clinical covariates with
no treatment variable.
Although some approaches developed for ITR derivation become widely used, spe-
cific research questions about applying precision medicine in clinical practice remain
to be addressed, such as validating an existing ITR, procuring ITR with multiple
views, and dealing with missing clinical data. Motivated by these practical chal-
lenges in clinical studies, this dissertation plans to develop a few new statistical
learning methods to extend the techniques currently used for ITR derivation. In
particular, we focus on the method of OWL in the establishment of ITRs due to its
stable performance and easy applications for clinical settings.
Our first project in Chapter II considers the problem of utilizing promising candi-
date biomarkers to update the existing ITRs in order to achieve better clinical benefits
for patients. It is motivated by a randomized clinical trial comparing the therapeutic
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effects of two medications, pioglitazone and gliclazide, in treating patients with type
2 diabetes (Charbonnel et al., 2005). The outcome of interest is the reduction rate of
fasting plasma glucose (FPG) over the 52 weeks of treatment. An existing ITR was
established involving age, body bass index (BMI) and baseline FPG, with the first
two being common demographic variables and the last one being the baseline refer-
ence of the individual FPG level. With some new candidate biomarkers available, like
Hemoglobin A1c (HbA1c), fasting insulin, and total cholesterol, we are interested in
figuring out which biomarkers may be included into and update the existing ITR to
achieve better clinical benefits if the new decision rule was implemented for the whole
population. In order to select useful biomarkers, in Section 2.3 we propose, examine
and illustrate a new statistical framework, termed net benefit index (NBI), to ana-
lytically and numerically quantify added values of candidate biomarkers when they
are included in the existing ITR. NBI works by quantifying a contrast between the
resulting gain-and-loss of treatment benefits when a biomarker enters an existing ITR
to reallocate patients in treatments. To account for sampling uncertainty in assessing
the contribution of a biomarker, we propose an NBI-based test statistic for evaluating
the significant improvement over the existing ITR, where the empirical null distri-
bution is constructed via the method of stratified permutation by treatment arms.
Simulation experiments in Section 2.4 show that the proposed NBI method achieves
high sensitivity and specificity in selecting the useful biomarkers to improve ITR, re-
sulting in a cost-effective selection of useful biomarkers and a better ITR with higher
prediction accuracy in terms of the underlying correct treatment for patients. Apply-
ing NBI to the motivating diabetes trial, in Section 2.5 we find that baseline fasting
insulin is an important biomarker that leads to an improvement over the existing ITR
based only on patient’s age, BMI and baseline FPG to reduce the FPG concentration
over a period of 52-weeks’ treatment.
Chapter III and Chapter IV focus on the estimation of ITRs for precision nutri-
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tion. Different from precision medicine, precision nutrition aims to derive the optimal
ITR to maximize the benefits for subjects in taking nutritional supplementations,
such as vitamins, calcium, and hormone therapy. Both chapters are motivated by
a randomized clinical trial in the third cohort study of the Early Life Exposure in
Mexico to ENvironmental Toxicants (ELEMENT) Project (Perng et al., 2019). The
central objective of this clinical trial is to study the effect of daily intake of calcium
supplementation by pregnant women in reducing infant blood lead concentration. It
has been demonstrated in the literature that at the population level, dietary calcium
supplementation can reduce maternal lead concentration in blood and thus alleviate
lead exposure to infants through blood transfusion and breastfeeding (Ettinger et al.,
2007; Janakiraman et al., 2003; Gulson et al., 2004; Téllez-Rojo et al., 2006a). Our
interest lies in establishing an ITR that would guide pregnant women for their daily
intake of calcium supplementation, which presents a useful nutritional intervention
offered in nutritional counselling. This precision nutritional rule delivers guidelines
under tailored individual dietary patterns, lifestyle and living conditions. The core
problem in these two chapters pertains to the existence of multiple benefit outcomes,
arising from practical issues related to different degrees of clinical relevance, measure-
ment qualities, and missing data. They all present great technical challenges to the
derivation of ITRs.
Chapter III presents a new method, termed synergistic self-learning (SS-learning),
to address two major challenges for ITR derivation in the presence of multiple clinical
outcomes, including heterogeneous multidimensional outcomes and complex missing
data patterns. SS-learning can effectively synergize heterogeneous features of multi-
ple training data sources in the derivation of ITRs. SS-learning works in a weighted
self-learning paradigm, in which individual outcomes of different clinical relevance
are incorporated separately as weights in SVM, and the estimated subgroup labels
from low quality data sources are iteratively calibrated with information from high
4
quality data sources. With the introduction of additional tuning parameters, the rela-
tive contributions from respectively low- and high-quality data sources are tuned in a
greedy way according to a criterion through minimization of the sum of squared errors
(SSE) of the predicted benefits. We prove the algorithmic convergence of the pro-
posed SS-learning method. We apply SS-learning to analyze the ELEMENT calcium
supplementation trial and identify several important predictors in the construction
of an optimal ITR. This resulting ITR would give a larger reduction of maternal
lead exposure to infants at birth during pregnancy should it be implemented to the
population of pregnant women. The performance of SS-learning is also examined by
comprehensive simulation studies, showing that SS-learning outperforms the standard
OWL method in ITR derivation with respect to the prediction accuracy of the under-
lying correct treatment assignment as well as the estimated benefit of lead exposure
reduction at population level.
Chapter IV further extends SS-learning to longitudinal self-learning (LS-learning)
to accommodate longitudinal benefit outcomes with missing data. In real-world clin-
ical trial practice, missing data are pervasive, which may occur in complicated ways.
The mechanism of missing completely at random (MCAR) or that of missing at ran-
dom (MAR) may not be the case in reality. Therefore, a method that can deal with
missing data under the mechanism of not missing at random (NMAR) is needed. For
ITR derivation in this chapter, we follow the idea of pattern mixture models (Little,
2008) to first stratify subjects based on their subject-specific endpoint measurements,
and then integrate the longitudinal outcomes measured at different time points (terms
as surrogate endpoint). LS-learning assumes the primary endpoint benefit outcome
being the one measured at the last longitudinal visit, while surrogate benefit out-
comes are those measured longitudinally prior to the last endpoint. In the presence
of missing endpoint benefit outcomes, we utilize surrogate endpoints in ITR deriva-
tion. A technical difficulty of ITR derivation is that there may exist many surrogate
5
benefit outcomes, leading to a case of many tuning parameters in the application
of LS-learning. This results in a considerable cost of computation time on parame-
ter tuning if the greedy tuning method proposed in Chapter III were employed. To
overcome this computational challenge, we introduce a scaled tuning procedure that
works by specifying the tuning parameters as a systematic function of the observa-
tional time. In this way, we can significantly reduce the total number of parameters
to be tuned to speed up computation. Simulation experiments illustrate that LS-
learning with scaled tuning outperforms the standard OWL in ITR derivation with
respect to the prediction accuracy for the underlying correct treatment assignment.
Applying LS-learning with the scaled tuning scheme to the calcium supplementation
trial, we found several important predictors, including dietary intake of CA, fiber, Fe
and Zn, in the derivation of ITR. The estimated ITR results in the highest long-term
reduction of maternal lead exposure for infants at age of 3 years old.
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CHAPTER II
Net Benefit Index: Assessing the Influence of a
Biomarker for Individualized Treatment Rules
2.1 Introduction
Utility of the newly discovered biomarkers, such as omics-markers, from basic sci-
ences to facilitate better and more cost-effective clinical practice is of critical impor-
tance in translational medicine. In connection to the emerging field of personalized
medicine, one central task is to update the existing individualized treatment rules
(ITRs) using new biomarkers with the aim to receive better clinical benefit. A no-
ticeable shortcoming in the current statistical literature of personalized medicine is
a lack of such methods to evaluate the significance of individual biomarkers in im-
proving the existing ITRs. Perhaps this has been regarded as a small mathematical
problem, but such methodological need is not easy to be addressed appropriately
given many practical constraints involved, such as clinical benefit and medical cost
associated with the inclusion of such biomarkers in daily clinical practice. This pa-
per is intended to fill in this technical gap with a specific objective of developing a
new statistical procedure to assess the usefulness of a biomarker in the context of
personalized medicine.
Motivated from a randomized clinical trial comparing two drugs, i.e. pioglitazone
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and gliclazide, on treating Type 2 diabetic patients, we propose, examine and illus-
trate a new statistical framework, termed as net benefit index (NBI), to analytically
and numerically quantify added values of candidate biomarkers when they are used
to update an existing ITR. We consider an existing ITR involving age, body mass
index (BMI) and baseline fasting plasma glucose (FPG) to maximize the reduction
of FPG after 52 weeks of treatment. With several new variables like Hemoglobin
A1c (HbA1c), fasting insulin, etc., we want to evaluate their added values, and de-
cide which one or ones can significantly improve the existing ITR. Added value of
a promising biomarker is gauged by a contrast between the resulting gain and loss
of clinical benefits from reallocations of treatments through a revised ITR with the
utility of this new biomarker. Reallocation is optimized by outcome weighted learning
(OWL) (Zhao et al., 2012). In addition, we consider an NBI-based test for signifi-
cance of a certain added value in which the empirical null distribution is generated
via stratified permutation by treatment arms. Through this procedure, biomarkers
that significantly improve an existing ITR are sequentially selected to revise current
allocation rules, where the biomarker selection is controlled under false discovery rate
(FDR) to avoid the issue of overfitting. Note that overfitting in terms of the number
of biomarkers is practically unattractive due to higher costs and longer time spent
on collecting samples that essentially produce redundant information, which may
undermine the accuracy and interpretation of an estimated ITR.
While NBI allows to evaluate the contribution of new biomarkers under controlled
FDR, it avoids some other problems known in existing biomarker selection techniques
in the context of personalized medicine. In the field of decision-making, variable selec-
tion should target primarily at prescriptive variables that help prescribe the optimal
action, instead of the predictive variables that reduce the variability and increase the
accuracy of an estimator. A prescriptive variable has to have a qualitative interaction
with the treatment (Gunter et al., 2011). A variable is said to qualitatively inter-
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act with the treatment if there exists at least two distinct, non-empty sets within
the space of the variable, for which the treatment arms that maximize the expected
clinical benefit are distinct (Gunter et al., 2011). Qian and Murphy (2011) proposes
a two-stage Q-learning (Q denoting “quality”) (Watkins , 1989) procedure that em-
ploys the l1-penalty for variable selection to estimate an optimal ITR. Lu et al. (2013)
develops a penalized regression framework, known as a kind of A-learning (A denot-
ing “advantage”) (Murphy , 2003) that allows to simultaneously estimate an optimal
ITR and to select an important variables. However, neither of these two methods
specifically targets at the selection of prescriptive variables. Gunter et al. (2011)
proposes two variable-ranking criteria, U-score and S-score, for variable selection via
qualitative interactions. But one limitation of these criteria is the ignorance of the
correlations between the variables. To overcome this issue, Fan et al. (2016) devel-
ops a sequential advantage selection (SAS) method based on a modified version of
S-score. SAS sequentially evaluates additional values of new variables via qualita-
tive interactions, so that it can avoid identifying any variables marginally important
but jointly unimportant. However, SAS lacks its direct relevance in clinical practice
as it does not directly optimize treatment benefit objective for ITR, instead build-
ing models with sequentially added interaction terms under a statistical criterion of
mean squared error. Different from these existing methods, NBI has the following
advantages: (i) NBI directly optimizes treatment grouping labels to maximize the
expected clinical benefit; (ii) NBI selects important prescriptive variables beneficial
for treatment allocation; (iii) NBI is naturally applicable for non-linear decision rules
due to the invocation of support vector machine (SVM); (iv) NBI sequentially selects
biomarkers into an existing ITR through FDR control.
The remainder of the chapter is organized as follows. Section 2.2 introduces the
motivating diabetes clinical trial, followed by the framework of NBI for biomarker
assessment in Section 2.3. Section 2.4 evaluates the proposed NBI test through sim-
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ulation experiments. The NBI method is illustrated by the motivating clinical trial
in Section 2.5. Section 2.6 contains some concluding remarks. Detailed introduction
of OWL and some additional simulation results are available in Appendix A-D.
2.2 Application: A Diabetes Clinical Trial
This is a randomized control and double-blind trial that aims to compare the
therapeutic effects of pioglitazone and gliclazide in treating patients with Type 2 di-
abetes. Pioglitazone and gliclazide are two common oral medications with different
therapeutic mechanisms for the treatment of Type 2 diabetic patients. A total of
1,270 patients with Type 2 diabetes were recruited into the trial. All the eligible
patients were randomized to a 52-week treatment period. The outcomes of interest
is the change of FPG between the last post-treatment measurement and baseline.
FPG was measured repeatedly at baseline and at week 4, 8, 12 up to 52. Other vari-
ables measured at baseline included age, BMI, HbA1c, fasting insulin, high-density
lipoproteins (HDL), low-density lipoproteins (LDL), aspartate transferases (AST),
alanine transferases (ALT), total cholesterol, triglycerides, creatinine, and gamma-
glutamyl transferase (GGT). After deleting subjects with missing data, a sample of
830 patients remains available for analysis, with 424 assigned to pioglitazone and 406
assigned to gliclazide. Due to loss of follow-up, some of the patients had the last
post-treatment measurement taken at week 32 or 42, resulting in a shorter period of
treatment. Charbonnel et al. (2005) performs a non-inferiority test for the differential
treatment effects between these two drugs on the reduction of FPG and illustrates a
significantly greater mean reduction of FPG by pioglitazone (2.4 mmol/L) than by
gliclazide (2.0 mmol/L), with a treatment difference of 0.4 mmol/L in favour of piogli-
tazone (95% CI 0.1 to 0.7 mmol/L). The comparison of FPG reduction rate illustrates
that pioglitazone leads to a more effective FPG reduction (0.049 mmol/L/week) than
gliclazide (0.038 mmol/L/week), with a treatment difference of 0.011 mmol/L/week
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Figure 2.1: (a) Effects of pioglitazone and gliclazide on reducing fasting plasma glu-
cose (FPG) during the 52-week period. (b) Average reduction rate of
FPG by pioglitazone and gliclazide in the 52-week period.
(95% CI 0.003 to 0.019 mmol/L/week) (Figure 2.1).
The previous analysis finds a significant treatment difference on population av-
erage between pioglitazone and gliclazide in reducing FPG. However, for individual
patients, some taking pioglitazone may receive little benefit, while some taking gli-
clazide may receive significant benefit. Given such heterogeneous responses to these
drugs, an optimal ITR is deemed necessary to increase the benefit by shuffling pa-
tients in a systematic way to assign each patient to the “right” drug. This purpose of
reallocation may be formulated and achieved with the aim to maximize the expected
FPG reduction via a revised drug allocation rule. Consider a simple preliminary ITR
that involves only baseline FPG, age and BMI, denoted by ITR(b.FPG, age, BMI).
Age and BMI are two commonly used demographics for treatment assignment, while
baseline FPG is a key clinical factor representing a personal reference level for the
target endpoint. Among the available additional candidate biomarkers, we want to
determine which ones may provide significant added values to improve ITR(b.FPG,
age, BMI); if there are some, the expanded ITR is expected to provide higher treat-
ment benefit than that given by the preliminary ITR.
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2.3 Formulation
2.3.1 Outcome Weighted Learning and Optimal ITR
Consider a two-armed randomized clinical trial where each patient is randomly
assigned a treatment A ∈ A = {−1, 1}. A = −1 is the traditional treatment, say
gliclazide. A = 1 is the new treatment, say pioglitazone. Complete randomization
implies that the treatment allocation scheme is independent of patients’ prognostic
variables, denoted as X = (X1, ..., Xd)
ᵀ ∈ X ⊆ Rd. Potential clinical benefit B∗(A) is
the outcome that would result if a patient were assigned to A. Since each patient takes
only one treatment, the observed clinical benefit is given by B = I(A = 1)B∗(1) +
I(A = −1)B∗(−1), which is determined by A. The other potential clinical benefit
is latent with no data captured. Suppose that B is bounded with a larger value of
B being clinically more desirable. The primary aim of personalized medicine is to
establish a decision rule D(X), a mapping X → A, that maximizes the expectation
of the clinical benefit. The following three assumptions are typically required for
computing the expectation of the clinical benefit (Berkane, 2012): a) Consistency
assumption: B = I(A = 1)B∗(1)+I(A = −1)B∗(−1); b) No unmeasured confounders
assumption: A ⊥ {B∗(a)}a∈A | X; c) Positivity assumption: P{P (A = a | X) >
0} = 1,∀a ∈ A.
In this paper, the optimal ITR refers to the decision rule D∗(X) that maximizes





, which according to Zhao et al.
(2012) may be formulated as a weighted classification problem that can be solved by
SVM in the context of OWL (see details in Appendix B). The optimization problem
of OWL has very relevant interpretations to our definition of NBI. For patients with
large observed benefits, the optimality encourages to allocate the same treatment
type as the one previously assigned. Conversely, for those receiving small observed
benefits, the optimality tends to assign the alternative treatment type. Note that in
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the diabetes trial, the actually implemented allocation is complete randomization, i.e.
P (A | X) = P (A) = 0.5. But this might not give the best personalized drug allo-
cation rule as randomization primarily aims to control confounding not to maximize
treatment benefit. Clearly, the optimal decision rule D∗(X) will give a higher overall
clinical benefit in comparing to completely randomized trial.
2.3.2 Treatment Reallocation
Let D(X) be a decision rule based on featuresX. The optimization for D(X) im-
posed by OWL encourages concordant treatment assignment on patient who receives
clearly treatment benefit. In other words, with the invocation of OWL, patients
who are assigned D(X) = A tend to have larger benefit than those who receive
D(X) 6= A. Denote an existing decision function by fe(Xe) and the corresponding
decision rule by De(Xe) based on the existing variables Xe. Likewise, denote an up-
dated decision function by fu(Xe,Xu) and the corresponding updated decision rule
by Du(Xe,Xu) by involving new variables Xu. Under decision rules De(Xe) and
Du(Xe,Xu), there exist two subgroups of patients who receive the same treatment
allocation, i.e. De(Xe) = A and Du(Xe,Xu) = A, respectively. For those patients
who are assigned the same treatment by De(Xe) and Du(Xe,Xu), the inclusion of a
new biomarker does not lead to any benefit gain. Thus they should be excluded from
the assessment of the difference caused by the biomarker. In other words, only those
patients who are assigned a different treatment by Du(Xe,Xu) from that by De(Xe)
should be used to define an effective amount of clinical benefit.
Figure 2.2 illustrates a simple example showing the different groups of subjects
included in the calculation of V (D) when new biomarker X2 is used in the learning
of an updated decision function f(X1, X2) compared to f(X1). Subjects randomly
assigned to A = 1 and A = −1 in the trial are denoted by circles and triangles. The
sizes of circles and triangles reflect the magnitude of clinical benefit, with a bigger
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Figure 2.2: Changes of the subjects included in the calculation of V (D) when new
biomarker X2 is included in the estimation of the decision function. Sizes
of the circles and triangles reflect the magnitude of the clinical benefit B.
Black circles and triangles are the subjects included in the calculation of
V (D) since they have D(X) = A. Subjects in group “gain” and “loss”
are pointed by arrows. (a) Decision function f(X1) estimated only on the
existing biomarker X1. (b) Decision function f(X1, X2) estimated on X1
and X2.
size corresponding to a larger benefit. Only those subjects in black are effectively
included in the calculation of V (D) since they are assigned the concordant treatment
D(X) = A. By comparing the black circles and triangles in Figure 2.2(a) and 2.2(b),
we can find that a circle and a triangle (pointed by arrows) are newly included in the
calculation of V (D), indicating that there is a gain as the consequence of reallocation
by f(X1, X2). At the same time, another circle and another triangle (pointed by
arrows) are excluded from the calculation of V (D), indicating that there is a loss.
Since the newly included subjects have larger benefit (larger size), the gain exceeds the
loss in the expected benefit value. Note that only subjects with f(X1)×f(X1, X2) < 0
will be included into the respective groups “gain” and “loss” since they have switching
allocations from D(Xe) to D(Xe,Xu). Technically, they are the ones responsible for
a difference in the calculation of V (D). It is conceptually appealing to quantify the
contrast between “gain” and “loss” to understand the influence of a new biomarker
for added value in personalized treatment allocation. We assume the following ethics
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conditional on reallocation treatment.
Assumption II.1. Let D(X) be an allocation rule based on variable X, and let
B(A | X) be the observed benefit when D(X) = A. Suppose ∀ε > 0, ∃δ(ε) < ε,
such that P{B(Ac | X) ≥ B(A | X) | B(A | X) < ε} ≥ 1 − δ(ε), where Ac is the
alternative treatment to A.
Assumption II.1 implies that when the clinical benefit of a patient receiving treat-
ment A tends to zero, with probability approaching to 1 there is no loss of benefit for
allocating the alternative treatment Ac to the patient.
2.3.3 Net Benefit Index (NBI)
Let Bi be the observed benefit value for each patient, i = 1, . . . , n. Denote Sgain
as the sample of patients in group “gain”, and Sloss as the sample of patients in group
“loss”. A net benefit index for a new biomarker Xu is defined as follows:
Definition II.1. (Net Benefit Index).
NBI(Xu) =
∑
i∈Sgain Bi/P (Ai |Xi)∑
i∈Sgain 1/P (Ai |Xi)
−
∑
i∈Sloss Bi/P (Ai |Xi)∑
i∈Sloss 1/P (Ai |Xi)
. (2.1)
Remark II.1. In the case of a randomized clinical trial, propensity P (Ai | Xi) =







Bi/nloss = BSgain −BSloss , (2.2)
which is actually the difference of the average observed benefits of Sgain and Sloss.
Clearly, NBI > 0 suggests that a new biomarker is potentially valuable to improve
the existing ITR.
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Remark II.2. To account for sampling variability, we propose a standardized NBI







, where s2gain and s
2
loss are
sample variances of observed benefits for Sgain and Sloss, respectively.
The calculation of NBI and standardized NBI for Xu is given by Algorithm II.1.
Note that the minimal sample size, ngain ≥ 5 and nloss ≥ 5, is required in the calcu-
lation of standardized NBI to have numerical stability.
Algorithm II.1 Calculation of standardized-NBI(Xu)
1: Establish models fe(Xe) and fu(Xe, Xu) using OWL on a training dataset.
2: Get classifications De(Xe) and Du(Xe, Xu) for subjects in a NBI evaluation
dataset.
3: Characterize samples Sgain and Sloss by comparing De(Xe) and Du(Xe, Xu).
4: if ngain ≥ 5 and nloss ≥ 5 then
5: Calculate standardized-NBI(Xu) based on the values of B in Sgain and Sloss.
6: else Set standardized-NBI(Xu)=0.
2.3.4 Test for Significant NBI
NBI> 0 is only suggestive subjective to sampling uncertainty, which may further
be made rigorous by hypothesis testing. For a practical point of view, we hypothesized
that Du(Xe,Xu) should not be inferior to De(Xe). Thus, we consider the following
hypotheses: H0: the new biomarker does not improve ITR; against Ha: the new
biomarker improves ITR. Let µgain and µloss be the expected benefits in the “gain”
and the “loss” population respectively. The hypotheses can be stated as a two-
sample mean comparison: H0 : µgain = µloss; against Ha : µgain > µloss. We will apply
the standardized NBI to perform the hypothesis of two sample mean comparison.
However, it is difficult to derive the distribution of standardized NBI. Therefore,
we invoke the empirical null distribution of the standardized NBI to generate the
p-values.
Remark II.3. Different from the standard two-sample test, here Sgain and Sloss are
random sets generated by a resulting optimal reallocation of treatments under a com-
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mon overall optimal benefit objective function. Thus, there exists a certain shared
action in group membership labeling, which leads to a dependence between these two
sets. However, when conditional on the memberships of Sgain and Sloss, we have the
conditional independence, which leads to a standard unequal variance two-sample t-




loss/nloss ∼ t(ν), where
δ = µgain − µloss and ν = ν(ngain, nloss, s2gain, s2loss) is degrees of freedom. Clearly, the
sizes of both sets, ngain and nloss, are random and correlated in ν. Since the labels in
Sgain and Sloss have a rather complicated and unknown joint distribution, the marginal
distribution of the t-statistic is not available to make inference. Thus, we invoke the
empirical null distribution to obtain p-values.
To do so, we propose to create a null variable Xnull via the means of permuta-
tion with projected residuals ri = Xu,i − Ê(Xu,i | Xe,i), i = 1, . . . , n as detailed in
Algorithm II.2.
Algorithm II.2 Generation of empirical null distribution for standardized-NBI(Xu)
1: if Xe 6= Null then
2: Model Xu = g(Xe)+ ε, where g(·) is a suitable function independent of A and
B.
3: Get residuals ri = Xu,i − Ê(Xu,i |Xe,i), i = 1, . . . , n.
4: else Let ri = Xu,i.
5: for l = 1, . . . , L do (L is the number of permutation replicates).
6: Permute the residuals conditional on A; get the permuted residuals rpl,i, i =
1, . . . , n.
7: Values of Xnull,l are generated as Xnull,l,i = Ê(Xu,i | Xe,i) + rpl,i, i = 1, . . . , n.
8: Calculate standardized-NBI(Xnull,l) using Algorithm II.1.
Assumption II.2. The new variable Xu can be expressed by an additive model Xu =
g(Xe) + ε of the existing variables Xe and the error term ε. Discussion of violations
of Assumption II.2 is included in Section 2.6.
Algorithm II.2 outputs the empirical null distribution of the standardized NBI, and
the p-value is given as p = #{standardized-NBI(Xnull) > standardized-NBI(Xu)}/L.
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The invocation of stratification by treatment arm in the permutation test is to re-
tain the difference between the underlying distributions of the residuals across two
treatment groups. Pooling the residual distributions together while performing per-
mutation test would ruin the interaction effect between treatment and biomarkers.
Since our major interest is to evaluate the added value of a biomarker when we have
an existing ITR, we will focus our method on the situation whenXe 6= Null in the fol-
lowing simulation studies and real data analysis. Simulations results with Xe = Null
are included in Table C.1 in Appendix C.
When there are several new variables under screening, say m, it is necessary to
control FDR to ensure a balance of sensitivity and specificity. To proceed, we propose
a forward selection method, Algorithm II.3, that sequentially adds the currently most
significant variable with the smallest p-value into a current model at each step until
no more variable to be added. The significant variables at each step are identified as
those passing the FDR control through the Benjamini-Hochberg procedure.
Algorithm II.3 Sequential forward variable selection based on NBI test
1: Set m = dim(Xu).
2: while m > 0 do
3: Get pj for Xu,j, j = 1, . . . ,m with the existing model involving Xe by NBI
test.
4: Order p(1) ≤ · · · ≤ p(m), each corresponding to H(j): Xu,(j) does not improve
ITR.
5: Find jmax = max
j
{j : p(j) ≤ jmq}, where q ∈ (0, 1) is the chosen target FDR
control.
6: if jmax exists then Update Xe = {Xe, Xu,(1)},Xu = Xu \ Xu,(1), and set
m = m− 1.
7: else Stop.
2.4 Simulation Experiments
In this section, we conducted extensive simulations to evaluate the finite sample
performance of the proposed NBI method.
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2.4.1 Single-variable-based Decision Rule Evaluation
The first simulation concerns a setting in which an existing ITR consists of two
variables X1 and X2, where Xi
i.i.d∼ U(0, 1), i = 1, 2. Suppose that a new variable Xu ∼
U(0, 1) becomes available, which is correlated with X2, namely Corr(X2, Xu) = ρ with
ρ ∈ {0.0, 0.2, 0.5, 0.8}. The following types of Xu are considered: (i) Xu = X3, an
important feature related to benefit B; (ii) Xu = X4, a noise variable unrelated to B.
Our goal is to assess the sensitivity (i.e. rate of detecting X3) and specificity (i.e. rate
of not detecting X4) by the proposed NBI test. Allocation of treatment A ∈ {−1, 1}
is independent of X with P (A |X) = 0.5. B is generated from a normal distribution
with mean µ = 0.5 + X1 + 2.0Af(X) and standard deviation σ = 1.0. Interaction
term Af(X) specifies a bimodal expected benefit that generates bifurcated benefit
outcomes. We consider the following three scenarios of true decision function f :
1) (Linear) f(X) = 1−X1 +X2 − 2X3;
2) (Binary) f(X) = 4{I(X1 > 0.1 ∩X2 < 0.75 ∩X3 > 0.25)− 0.5};
3) (Nonlinear) f(X) = 2.5{(X1 − 0.5)+ + (X2 − 0.2)+ − (X3 − 0.1)+}.
The sample size is set at n = 800, 1000, 1200. 5-fold cross-validation is used to
determine the training dataset to learn f and the NBI evaluation dataset to assess
Xu. We set type I error rate α = 0.05. Simulation is repeated for 1000 times.
Table 2.1 summarizes the discovery rates of X3 and X4 across different f based
on the proposed NBI method. It is shown that the sensitivity is high in detecting
the useful variable X3, and type I error has been well controlled for the noise variable
X4 at the nominal level 0.05. Table 2.2 reports the NBI values for X3 and X4.
Aligned with the high sensitivity, the corresponding NBI(X3) are all positive, implying
that the inclusion of X3 results in an improved ITR(X1, X2, X3), in which more
patients are assigned into their beneficial treatment arm in comparison to the previous
ITR(X1, X2). In contrast, all the NBI(X4) values are negative, indicating that the
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Table 2.1: Discovery rates for X3 and X4 in the single-variable-based decision rule
evaluation. (Discovery rate for X4 equals 1-specificity.)
ρ = 0.0 ρ = 0.2 ρ = 0.5 ρ = 0.8
scenario n X3 X4 X3 X4 X3 X4 X3 X4
linear 800 0.987 0.047 0.991 0.056 0.984 0.057 0.931 0.053
1000 0.998 0.054 0.997 0.043 0.992 0.051 0.958 0.055
1200 0.999 0.059 1.000 0.051 0.998 0.052 0.974 0.053
binary 800 0.932 0.051 0.946 0.049 0.956 0.050 0.815 0.050
1000 0.956 0.049 0.967 0.034 0.971 0.046 0.866 0.051
1200 0.968 0.054 0.975 0.048 0.972 0.045 0.927 0.050
nonlinear 800 0.977 0.053 0.987 0.055 0.973 0.055 0.854 0.050
1000 0.984 0.055 0.996 0.058 0.983 0.042 0.906 0.044
1200 0.995 0.043 0.997 0.049 0.994 0.054 0.934 0.036
inclusion of X4 results in a worse updated ITR(X1, X2, X4) that assigns more patients
into their non-beneficial treatment arm. When FDR is controlled, the chance of X4
entering the updated ITR is slim, and the resulting decline in outcome of benefit is
indeed ignorable.
2.4.2 Multiple-variable-based Decision Rule Evaluation
The second simulation uses the same setup of the base ITR(X1, X2) specified
in Section 2.4.1. Now we consider multiple signal and noise candidate biomarkers
Xj ∼ U(0, 1), j = 3, . . . , 12, in which only X3 and X4 are signal biomarkers involved
in the optimal ITR. The correlation structure of the variables is that Corr(X3, X5) =
Corr(X4, X6) = 0.5, and Corr(Xs, Xt) = 0.2, s, t ∈ {7, . . . , 12}, s 6= t. The mean
parameter of benefit B is set as µ = 0.5 +X1 + 2.0Af(X). We consider the following
three scenarios of true decision function f :
4) (Linear) f(X) = 0.5(1 +X1 +X2 − 1.8X3 − 2.2X4);
5) (Binary) f(X) = 6{I(X1 > 0.12 ∩X2 < 0.88 ∩X3 > 0.2 ∩X4 < 0.8)− 0.5};
6) (Nonlinear) f(X) = (X1 − 0.9)+ − (X2 − 0.78)+ + (X3 − 0.1)+ − (X4 − 0.22)+.
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Table 2.2: NBI values for X3 and X4 in the single-variable-based decision rule evalu-
ation.
ρ = 0.0 ρ = 0.2
scenario n X3 mean (sd) X4 mean (sd) X3 mean (sd) X4 mean (sd)
linear 800 1.708 (0.547) -0.150 (0.636) 1.724 (0.556) -0.136 (0.653)
1000 1.700 (0.517) -0.139 (0.622) 1.693 (0.509) -0.194 (0.611)
1200 1.657 (0.445) -0.161 (0.614) 1.655 (0.442) -0.140 (0.611)
binary 800 3.139 (1.553) -0.155 (1.922) 3.192 (1.489) -0.217 (1.815)
1000 3.090 (1.449) -0.127 (1.827) 3.121 (1.382) -0.160 (1.835)
1200 3.075 (1.386) -0.081 (1.779) 3.069 (1.287) -0.046 (1.776)
nonlinear 800 1.793 (0.883) -0.224 (0.888) 1.862 (0.804) -0.265 (0.894)
1000 1.793 (0.791) -0.227 (0.883) 1.856 (0.740) -0.293 (0.889)
1200 1.770 (0.723) -0.228 (0.827) 1.855 (0.695) -0.277 (0.791)
ρ = 0.5 ρ = 0.8
scenario n X3 mean (sd) X4 mean (sd) X3 mean (sd) X4 mean (sd)
linear 800 1.594 (0.628) -0.127 (0.651) 1.125 (0.677) -0.158 (0.688)
1000 1.551 (0.552) -0.148 (0.626) 1.154 (0.563) -0.145 (0.626)
1200 1.503 (0.487) -0.171 (0.616) 1.152 (0.511) -0.132 (0.618)
binary 800 3.329 (1.499) -0.224 (1.855) 2.285 (1.888) -0.208 (1.760)
1000 3.172 (1.318) -0.056 (1.751) 2.345 (1.685) -0.154 (1.813)
1200 3.252 (1.231) -0.029 (1.756) 2.573 (1.622) -0.139 (1.653)
nonlinear 800 1.791 (0.796) -0.284 (0.903) 1.188 (0.832) -0.264 (0.932)
1000 1.801 (0.689) -0.329 (0.873) 1.293 (0.743) -0.343 (0.912)
1200 1.823 (0.672) -0.277 (0.841) 1.336 (0.692) -0.310 (0.811)
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We draw summary statistics under the FDR control set at 0.10. In addition to
those basic performance measures considered in Section 2.4.1, we add a comparison
of our NBI method on biomarker selection with SAS mentioned in Section 2.1 and
riskRFE (Dasgupta et al., 2019), a backward elimination method for variable selection
developed for SVM.
Table 2.3 reports some summary statistics, including (i) size: the total number
of selected biomarkers; (ii) true discovery rate (TDR): the number of correctly se-
lected biomarkers over size; (iii) Matthews correlation coefficient (MCC): MCC =
(TP×TN−FP×FN)√
(TP+FP)(TP+FN)(TN+FP)(TN+FN)
, where TP is true positive, TN is true negative, FP
is false positive and FN is false negative; (iv) correct classification rate (CCR). The
gold numbers are size = 2, TDR = 1, MCC = 1, and CCR = 1. Our NBI test tends
to give slightly conservative results with smaller size, a known consequence of FDR
control (Benjamini and Hochberg , 1995). Clearly, SAS and riskRFE pay a price of
overfitting with a large number of noise features selected, resulting in larger size and
smaller TDR. One lesson we learn from the simulation is that we may first run SAS
or riskRFE to select a relatively large pool of potential biomarkers, and then apply
NBI to control FDR. In this way, we could reach a desirable balance of sensitivity
and specificity. In regard to MCC, the proposed NBI test outperforms SAS and
riskRFE, except for the linear scenario, where SAS gives the highest MCC. In addi-
tion, the estimated ITR derived from the NBI method gives the highest CCR for the
binary scenario, but not for the linear and nonlinear scenarios, which is a limitation
of OWL. Some additional simulation experiments, including the small sample cases
where n = 200, the scenarios where Xe = Null and etc. are included in Appendix D.
2.5 Analysis of Diabetes Trial Data
We apply the proposed NBI methodology to analyze the motivating diabetes trial
described in Section 2.2. The outcome of benefit is the average reduction rate of
22
Table 2.3: Size, TDR, MCC, and CCR for variable selection based on NBI test, SAS
and riskRFE in the multiple-variable-based decision rule evaluation.
NBI
scenario n size (sd) TDR (sd) MCC (sd) CCR (sd)
linear 800 1.745 (0.709) 0.906 (0.222) 0.801 (0.242) 0.835 (0.081)
1000 1.813 (0.689) 0.922 (0.194) 0.828 (0.225) 0.852 (0.076)
1200 1.904 (0.622) 0.934 (0.170) 0.868 (0.202) 0.870 (0.070)
binary 800 1.844 (0.747) 0.894 (0.232) 0.813 (0.248) 0.765 (0.098)
1000 1.917 (0.705) 0.906 (0.215) 0.847 (0.232) 0.786 (0.095)
1200 1.924 (0.650) 0.919 (0.199) 0.863 (0.222) 0.805 (0.090)
nonlinear 800 1.805 (0.744) 0.904 (0.220) 0.802 (0.245) 0.818 (0.081)
1000 1.926 (0.738) 0.910 (0.199) 0.833 (0.225) 0.832 (0.075)
1200 1.913 (0.616) 0.929 (0.186) 0.869 (0.217) 0.847 (0.073)
SAS
scenario n size (sd) TDR (sd) MCC (sd) CCR (sd)
linear 800 2.817 (0.887) 0.774 (0.212) 0.831 (0.165) 0.971 (0.012)
1000 2.525 (0.732) 0.846 (0.193) 0.887 (0.146) 0.976 (0.010)
1200 2.339 (0.609) 0.898 (0.169) 0.926 (0.126) 0.979 (0.010)
binary 800 3.662 (1.244) 0.613 (0.215) 0.693 (0.187) 0.743 (0.014)
1000 3.286 (1.095) 0.677 (0.219) 0.751 (0.180) 0.744 (0.014)
1200 3.052 (1.007) 0.723 (0.217) 0.790 (0.174) 0.744 (0.014)
nonlinear 800 3.238 (1.102) 0.688 (0.219) 0.760 (0.180) 0.943 (0.013)
1000 2.915 (0.942) 0.752 (0.215) 0.813 (0.169) 0.948 (0.012)
1200 2.654 (0.817) 0.814 (0.205) 0.862 (0.157) 0.949 (0.011)
riskRFE
scenario n size (sd) TDR (sd) MCC (sd) CCR (sd)
linear 800 3.091 (1.003) 0.660 (0.222) 0.704 (0.222) 0.852 (0.056)
1000 2.815 (0.895) 0.732 (0.221) 0.773 (0.209) 0.869 (0.057)
1200 2.586 (0.781) 0.797 (0.218) 0.828 (0.204) 0.883 (0.052)
binary 800 3.498 (1.135) 0.636 (0.211) 0.716 (0.178) 0.737 (0.123)
1000 3.200 (0.990) 0.686 (0.209) 0.761 (0.169) 0.755 (0.124)
1200 2.909 (0.847) 0.745 (0.206) 0.810 (0.159) 0.779 (0.117)
nonlinear 800 3.142 (1.083) 0.651 (0.235) 0.689 (0.243) 0.834 (0.061)
1000 2.837 (1.009) 0.723 (0.230) 0.755 (0.219) 0.844 (0.059)
1200 2.576 (0.823) 0.791 (0.224) 0.812 (0.215) 0.857 (0.055)
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FPG over the 52 weeks of treatment. The base ITR is driven by three variables
Xe = {b.FPG, age, BMI}. Among those candidate biomarkers listed in Section 2.2,
we want to select some important ones and evaluate their added values to improve
the existing ITR.
We first performed a prescreening of these candidate biomarkers using SAS. Under
the cut-off point 0.01 for the proportion of the incremental sequential advantage, SAS
selects five variables potentially useful to update ITR, including baseline HbA1c,




u ) = 0.13− 0.14b.FPG− 0.02age− 0.17BMI− 0.05HbA1c
− 0.12b.fasting insulin− 0.13AST + 0.04triglycerides
+ 0.18creatinine,
We would allocate a patient with Type 2 diabetes to take pioglitazone if f̂ > 0 and
to take gliclazide if f̂ < 0. f̂SAS(Xe,X
SAS
u ) assigns 586 patients to pioglitazone and
244 patients to gliclazide. Following Murphy et al. (2001), we further calculate the
estimated value function by E∗n[I(A = D(X))B/P (A | X)]/E∗n[I(A = D(X))/P (A |
X)], where E∗n is the empirical average value. In order to make the comparison
from the same baseline, the same method (e.g. SVM, which is the learning algo-
rithm for both NBI and riskRFE) is used to calculate the estimated value function.
f̂SAS(Xe,X
SAS
u ) gives an estimated value function of 0.049, meaning that the ex-
pected average FPG reduction rate would be 0.049 mmol/L/week over 52 weeks if
f̂SAS(Xe,X
SAS
u ) were implemented for the whole population. The estimated value
functions given by complete random allocation and f̂SAS(Xe) are 0.048 and 0.052
respectively, indicating that XSASu does not improve the existing decision rule as far
as the estimated value function concerns. We then performed a biomarker screening
using riskRFE, which selected three variables potentially useful to update the existing
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u ) = −1.48− 0.08b.FPG + 0.37age + 1.09BMI
+ 0.45b.fasting insulin + 0.53creatinine + 0.97GGT,
f̂riskRFE(Xe,X
riskRFE
u ) assigns 527 patients to take pioglitazone and 303 patients to
take gliclazide. The estimated value function given by f̂riskRFE(Xe,X
riskRFE
u ) is 0.051,
even slightly smaller than that given by f̂riskRFE(Xe), which is 0.052, indicating that
XriskRFEu is not actually improving the existing ITR.
A clinically relevant question to the above estimated decision rules is whether the
selected candidate variables in XSASu and X
riskRFE
u are really influential to ITR, or
whether we may further reduce XSASu and X
riskRFE
u to achieve a more cost-effective
ITR. We then applied the proposed NBI test. It turns out that baseline fasting




u ) = −1.30− 0.07b.FPG + 0.39age + 2.04BMI + 0.35b.fasting insulin,
which assigns 481 patients to pioglitazone and 349 patients to gliclazide. The esti-
mated value function of this OWL-updated treatment regime is 0.053, which is higher
than that given by f̂SAS(Xe,X
SAS
u ) and f̂riskRFE(Xe,X
riskRFE
u ), although f̂NBI(Xe,X
NBI
u )
only uses a single biomarker, baseline fasting insulin, to improve ITR. The estimated
value functions given by f̂NBI(Xe) is 0.052, indicating that the inclusion of X
NBI
u in
the decision rule also improves the ITR with respect to the expected average FPG
reduction rate.
Comparing the coefficients in the estimated decision rules, we notice that the






u ) and f̂NBI(Xe,X
NBI
u ) (e.g. age has a negative coefficient in
f̂SAS(Xe,X
SAS
u ) but positive coefficients in f̂riskRFE(Xe,X
riskRFE
u ) and f̂NBI(Xe,X
NBI
u )).
It may due to the following reasons. First, loading coefficients are estimated by con-
ditioning on other variables in the decision rule, and thus signs of these coefficients
are possibly different with different sets of predictors (which are correlated) used in
the construction of the decision functions. What matters the most is indeed the max-
imum treatment benefit, which is the primary objective of this learning procedure.
Although the signs of the coefficients are not directly interpretable in this type of
methodology, we would still see a great deal of concordance, in particular between
f̂riskRFE(Xe,X
riskRFE
u ) and f̂NBI(Xe,X
NBI
u ). This is because that NBI and riskRFE
are both based on support vector machine (SVM), while SAS is based on regularized
linear regression. Thus, the training procedures and estimating criteria are different
between SAS and NBI/riskRFE. With the inclusion of the selected variables XNBIu ,
f̂NBI(Xe,X
NBI
u ) improves the estimated value function by about 10% compared to
complete randomness. In regard to the clinical impact of our results, we would think
that the demonstrated improvement is clinically meaningful, especially for people on
the border line of diabetes, i.e. the so-called prediabetes. It is known that approxi-
mately 88 million adults - more than 1 in 3 - have prediabetes in the US. Of those
with prediabetes, more than 80% don’t know they have it. The 10% change may help
pre-diabetic people whose diagnostic values just cross the border line to be controlled
at the normal level.
In addition to the expected reduction rate of FPG, we also compare the expected
reduction rate of HbA1c, another outcome of interest in the trial. Preliminary analysis
identifies no significant difference between the HbA1c reduction rates for patients





not improve the existing ITRs with all the existing and updated decisions rules giving
the same estimated reduction of HbA1c, which is 0.031 mmol/L/week over the 52-
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week treatment. But it is still slightly higher than the value of 0.029 given by complete
random allocation A.
2.6 Concluding Remarks
In this article, we proposed a new biomarker assessment tool, termed as NBI,
that enables to evaluate added values of biomarkers for improving existing ITRs.
This new method can be used in both single and multiple-variable-based decision
rule evaluations. Extensive simulation studies demonstrate that our method can cor-
rectly identify signal biomarkers under various scenarios with desirable performances
in comparison to existing methods. Application of the proposed method to a real dia-
betes clinical trial reveals that baseline fasting insulin is an important biomarker that
can significantly improve an existing ITR involving age, BMI, and baseline fasting
FPG, for the allocation of pioglitazone or gliclazide to patients with Type 2 diabetes.
It results significant clinical benefit of average reduction rate of FPG during the 52
weeks of treatment.
NBI is an analog to net reclassification improvement (NRI), a seminal index that
has been extensively used to evaluate the usefulness of new markers for predicting
risk of developing diseases (Pencina et al., 2010). The proposed NBI is fundamentally
different from NRI in the sense that NBI pertains to reclassification with respect to
treatment group when class labels are not directly observed, rather based on out-
come of treatment. Pepe et al. (2014) demonstrated that false-positive conclusions
based on the NRI statistic were unacceptably high. However, our simulation studies
have illustrated that the false discovery rate is well controlled using the NBI method.
Vickers and Pepe (2014) pointed out that NRI weights reclassification (i.e. false pos-
itive and false negative) inappropriately, which may also be an underlying problem
of NBI. However, with no information of true label available in the setting of NBI,
appropriate weighting of false positive and false negative may be infeasible in prac-
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tice. Decision curve analysis (DCA) (Vickers and Elkin, 2006) is another commonly
used method for comparing multiple treatment decision rules to select the optimal
one that maximizes the outcome of interest. The formulation of DCA relies on the
calculation of a net benefit, which is the relative harm of a false-positive and a false-
negative. Similarly, it is infeasible to apply DCA in our setting since we never know
the underlying true labels for patients in a clinical trial in practice.
NBI is naturally applicable for non-linear decision rules due to the invocation
of SVM, in which different kernels (e.g. Gaussian kernel) can be easily applied. We
would like to clarify two points in the usage of kernels: (i) kernel is used exclusively to
model the conditional distribution of R given X, and (ii) the assumption of additive
errors in the generation of Xnull is imposed on the conditional distribution of Xu
given Xe. Thus, the additivity assumption does not influence the relationship (or
the decision rule) between R and X characterized by kernel in the generation of the
empirical null distribution. In order to generate the null distribution for NBI, a certain
assumption on the influence of random errors on signals is inevitable. In this paper, we
adopted the classical additive error assumption, which can be violated in the practice.
In order to check the validity of the additive error assumption, we suggest first to run
a residual diagnosis. If it indicates that the error is not additive, i.e. Xu = f(Xe, ε),
we can apply Taylor Expansion to the function f(Xe, ε) and use a generalized additive
model (GAM) to model Xu on Xe. Then permutation test can be performed based
on the new error term ε′ = Xu − ĜAM(Xe), or ε′′ = {Xu − ĜAM(Xe)}/
√
θ̂(Xe) if
we assume the variance of ε′ can be modeled by a function θ(Xe).
One future direction of this study is to extend this methodology to multiple treat-
ment settings since clinical trials sometimes have more than two treatments in prac-
tice. In addition, it may be desirable to extend the method to situations where clinical
benefit outcomes are categorical or time-to-event. With increasing interest and re-
search in dynamic treatment regimes, we may also extend the NBI test to settings
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with multiple decision time points. Due to the number of replicates required by the
proposed permutation test as well as the computation time needed for SVM, the pro-
posed method may run into high computational demand. The algorithm can become
faster if a theoretically justified null distribution is available for the NBI test statistic,
which is worth an exploration in our future research.
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CHAPTER III
Synergistic Self-Learning Approach to Establishing
Individualized Treatment Rules from Multiple
Benefit Outcomes
3.1 Introduction
According to the developmental origins of health and disease (DOHaD) hypoth-
esis, environmental exposure before and immediately after birth may influence the
developmental health and well-beings of children during their infancy and even later
in their adulthood (Wadhwa et al., 2009). Prenatal exposure to toxic agents, ma-
ternal lifestyle, and maternal nutrition intake have been reported as major factors
that directly affect embryonic development. A vast literature has unveiled that lead
is detrimental on human neurobehavioral and cognitive development, particularly on
children (Chen et al., 2005; Hornung et al., 2009; Wasserman et al., 2003; Téllez-Rojo
et al., 2006b; Hu et al., 2006; Braun et al., 2012). It is demonstrated that both blood
and bone lead levels of children are associated, in an inverse direction, with their in-
telligence. Therefore, it is important to control lead exposure to children in order to
protect their neurodevelopment. In addition to the environmental lead exposure after
birth, the in utero exposure to lead that fetuses receive comes solely from maternal
nutrients. Thus, the study of maternal lead control during their pregnancy is of great
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importance for maternal and child health.
One of the leading cohort studies in this field is the Early Life Exposure in Mexico
to ENvironmental Toxicants (ELEMENT) Project (Perng et al., 2019). The ELE-
MENT project is an over 25-year mother–child pregnancy and birth cohort carried
out in Mexico, where regulations to prevent the use of lead in commodities such as
pigments, glaze, paint as well as gasoline were established only in 1991, resulting in
a serious problem of lead exposure to pregnant women even in late 20th Century
compared to the USA, where the control of lead usage started since 1970. One of
the major objective of ELEMENT is to study the effect of maternal lead exposure on
infant health outcomes. A lot of previous studies have discovered that mobilization
of maternal cumulative lead storage from bones (e.g. patella and tibia) into blood
circulation (Gulson et al., 1995, 2003; Hu and Hernandez-Avila, 2002) is one of the
important sources that contribute to maternal blood lead levels. Thus, blocking or
reducing the amount of lead released into maternal blood circulation from bones is
a significant preventive measure to minimize fetal lead exposure, and this may be
achieved by calcium, a lead blocker. Many studies, including several published works
from the ELEMENT Project, have demonstrated that dietary calcium supplementa-
tion can reduce maternal lead concentrations in blood by reducing bone resorption of
women during pregnancy (Ettinger et al., 2005, 2007; Janakiraman et al., 2003; Gul-
son et al., 2004; Téllez-Rojo et al., 2006a). All these studies focus on the population-
wise effect of calcium supplementation on reducing the blood lead concentration of
pregnant women, which ignores the heterogeneity of individual response to calcium
supplementation. Clearly, the calcium treatment effect size varies from one mother
to another; one taking the calcium supplement may have a significant reduction in
blood lead, while another in the same treatment arm may not have a strong effect
due to various reasons, e.g. there is enough daily dietary calcium intake. Thus, in
addition to evaluating the population-average effect of calcium on the whole study
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participants, establishing an individualized treatment rule (ITR) is of clinical impor-
tance to pregnant women, useful in precision nutritional counselling and guidelines
on tailored individual dietary patterns, lifestyle and living conditions.
The major objective of this article is to establish an ITR for pregnant women
based on their characteristic features to take calcium supplementation in order to
maximize the reduction of maternal lead exposure to infants. The establishment of
a well-performing and robust ITR requires a large sample size of high quality data
with measurements of the clinical outcome we want to maximize, i.e. the reduction
of lead exposure to infants in the ELEMENT Project. As we can see from the EL-
EMENT data (more details will be discussed in Section 3.2), there is only a small
number of measurements of the primary clinical outcome, the cord blood lead con-
centration, due to biosample collection difficulties. The derived ITR based on such a
small amount of data will definitely suffer from its robustness and reproducibility. A
straightforward idea to solve this problem is to integrate some secondary outcomes
of interest, such as maternal blood lead concentration from the third trimester and
infant blood lead concentration at 3-month age, with large sample sizes into the es-
timation of ITR. In a randomized clinical trial, it is not uncommon that in addition
to the primary outcome, many secondary outcomes such as quality-of-life measure-
ments are typically collected for the evaluation of broad treatment benefits. With
multiple benefit outcomes measured, two major challenges arise in ITR derivation.
On one hand, primary and secondary outcomes are of different clinical relevance to
the overall underlying health benefit. On the other hand, outcomes may be measured
separately from different subgroups of subjects, leading to different sample sizes and
complicated missing data patterns. Existing decision rule estimation methods in the
current literature, such as Q-learning (Qian and Murphy , 2011), outcome weighted
learning (OWL) (Zhao et al., 2012), and residual weighted learning (RWL) (Zhou
et al., 2017) are applicable only for a single outcome related to health benefit. To our
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best knowledge, there are no existing methods available in the literature that permits
the integration of multiple outcomes of different clinical relevance and data missing-
ness into a decision rule derivation. In order to fill in this important methodological
gap and address this technical need, we propose a new method, named synergistic self-
learning (SS-learning), that can incorporate both multiple outcomes and incomplete
data in the derivation of ITR.
The SS-learning method works in a weighted self-learning paradigm with char-
acterization of the relative contributions of respectively low- and high-quality data
sources. We analyzed the calcium supplementation trial from the ELEMENT Project
using SS-learning to derive an ITR for calcium supplementation assignment to preg-
nant women. Results based on SS-learning illustrate that 3-month infant blood lead
concentration is only slightly down weighted, while maternal blood lead concentra-
tion at the third trimester has a much lower clinical relevance, compared with cord
blood level in the derivation of ITR. The resulted ITR gives the highest estimated
lead exposure reduction compared with standard OWL either on the cord blood lead
outcome alone or on the combined outcomes with naive equal weighting (i.e. a naive
assumption of their equal clinical relevance). Our findings indicate that SS-learning
produces the largest reduction of infant blood lead concentration should the esti-
mated ITR be implemented to the whole study population. This optimality achieved
through personalized calcium supplementation allocation is clinically appealing in
precision nutrition. Moreover, we also identified several variables playing significant
roles in calcium supplement allocation, including dietary fiber, Fe, Zn and vitamin
C intake, indicating complicated interactions of nutrient contents in reducing mater-
nal lead exposure to infants. Although the focus of this article is in ITR derivation
for the calcium supplementation trial from the ELEMENT project, the developed
SS-learning method also contributes to the general statistical literature. Extensive
simulations show that it is very effective to improve classification rate with the use of
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the augmented training data. In addition, the algorithmic convergence of SS-learning
has also been proved.
The remainder of the chapter is organized as follows. We present an overview of
the calcium supplementation trial from the ELEMENT Project in Section 3.2. We
introduce SS-learning in Section 3.3. In Section 3.4 we evaluated the SS-learning
method through simulation studies with comparisons to existing methods, followed
by Section 3.5 where we analyzed data of the ELEMENT calcium trial with interpre-
tations and discussions. We give some concluding remarks in Section 3.6. Additional
numerical results and proof of the algorithmic convergence of SS-learning can be found
in Appendix E-G.
3.2 Application: Calcium Supplementation Trial
The data we analyzed is generated from the clinical trial in the third cohort study
of the ELEMENT Project. This clinical trial aims to assess effects of daily calcium
supplementation for pregnant women on reducing fetal blood lead concentration. A
total of 670 women recruited at their first trimester during 2001 to 2003 in Mexico City
participated in the clinical trial, with 334 participants randomized to receive a daily
dose of 1200 mg calcium supplement and 336 randomized to receive a placebo. The
maternal baseline variables used to establish the ITR include age, weight, total years
in school (school), status of marriage (married: yes/no), hrp parity (parity), dietary
fiber, Fe, Zn and vitamin C (VC) intake, and hemoglobin concentration (HgB). Blood
lead concentration measured from mother at first trimester (PBM) is also included as
a baseline reference of the maternal lead level. Maternal dietary calcium intake (Ca)
is included as a confounding factor for calcium supplementation.
Various benefit outcomes were measured during or after the trial, including ma-
ternal blood lead concentration at different trimesters of pregnancy, cord blood lead
concentration, and infant blood lead concentration up to 3-month of age. The primary
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measurement of fetal lead exposure is cord blood lead concentration since it directly
reflects the dose of lead in the exchange of nutrients between fetus and mother. Un-
fortunately, due to logistic difficulties of biosample collection, only a small number of
participants (n1 = 60) contributed cord blood samples at birth, leading to a limited
number of cord blood lead measurements. Deriving an ITR based on such a small
training dataset is at high stakes of reproducibility. One way to increase the size of
training data is to embrace other types of lead exposure measurements, albeit possi-
bly of lower clinical relevance. This motivates us to consider blood lead concentration
measured from infants at 3-month age (PBC3), as well as maternal blood lead con-
centration measured at the third trimester (PBM3), both of which are clinically much
easier to capture, giving rise to a much larger sample size (n2 = 245 and n3 = 366).
In comparison to the cord blood lead measurement, blood lead concentration at age
3 months may be slightly “contaminated”. Biologically, the effect of fetal lead expo-
sure from mother diminishes slowly overtime and may be altered by other sources of
lead in environment and breast milk; see Figure 3.1 for the mechanistic pathway of
fetal exposure to lead. Meanwhile, maternal blood lead concentration at the third
trimester do not directly reflect the lead exchange between mother and fetus during
pregnancy. Therefore, infant’s 3-month blood lead concentration and maternal blood
lead concentration at the third trimester are less relevant outcomes compared to cord
blood lead, as far as the efficacy of calcium supplementation concerns. In order to de-
rive an optimal ITR with improved reliability and reproducibility, we need a training
dataset not only of high relevance and precision to clinical outcome but also of large
sample size. To do so, we would like to apply an ITR estimation methods that ac-
commodate multiple outcomes of different relevance and sample sizes. The summary
statistics for the predictors used to establish the ITR are listed in Table 3.1.
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Figure 3.1: Mechanistic pathway of fetal exposure to lead. During pregnancy, the
increasing maternal bone turnover results in an elevated lead release into
plasma, which causes the increasing lead concentrations in cord blood and
breast milk. Such maternal lead exposure together with environmental
lead exposure result in an overall detrimental effect on the neurobehav-
ioral and cognitive development of infants.
Table 3.1: Summary statistics of the predictors in the calcium supplementation trial.
Mean (sd) and percentage values are shown, where p-values are obtained
from t-test and chi-square test for the numeric and categorical variables,
respectively.
Predictor Calcium Placebo p-value
age 26.9 (5.6) 25.9 (5.3) 0.017
weight 62.0 (10.7) 61.7 (10.0) 0.672
school 10.8 (2.9) 10.6 (2.9) 0.440
married 0.689 0.685 0.975
parity 2.0 (1.0) 2.1 (1.1) 0.409
HgB 13.2 (1.1) 13.2 (1.1) 0.774
Ca 11.1 (4.9) 10.8 (5.3) 0.531
fiber 24.2 (9.3) 23.4 (9.0) 0.237
Fe 13.4 (5.5) 13.4 (5.6) 0.995
Zn 9.7 (3.5) 9.7 (3.6) 0.893
VC 182.8 (90.4) 177.4 (86.5) 0.426
PBM 4.6 (2.6) 5.2 (3.7) 0.065
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3.3 Formulation of SS-learning
Here we first introduce the notations and basic settings of ITR derivation followed
by an introduction of a widely used decision rule estimation method OWL. Then we
propose the SS-learning method that can be applied to ITR estimation with multi-
ple outcomes with the parameter tuning procedure and the algorithmic convergence
theorem.
3.3.1 Basic Setting
Consider a training dataset S = {(B1i, B2i, . . . , Bmi, Ai,Xi), i = 1, . . . , n} col-
lected from a two-armed randomized clinical trial. X = (X1, . . . , Xd)
ᵀ ∈ X ⊆ Rd is
a d-dimensional vector of features. A ∈ A = {−1,+1} is a treatment (e.g. calcium
supplementation or placebo) assigned to each subject with probability P (A | X).
With complete randomization, P (A = 1 | X) = P (A = −1 | X) = 0.5. But
the propensity score P (A | X) can also be estimated by methods such as logistic
regression. (B1, B2, . . . , Bm) are multiple benefit outcomes. We assume that B1 is
of high relevance but difficult to measure, while (B2, . . . , Bm) are of low relevance
but easy to measure. Let S1 = {(B1i, Ai,Xi), i = 1, . . . , n1} be the subset of par-
ticipants with B1 measured, regardless of (B2, . . . , Bm) being measured or not. Let
Sl = {(Bli, Ai,Xi), i = 1, . . . , nl}, l = 2, . . . ,m be the subsets of participants with only
Bl measured. With no surprise, n1 = |S1| is much smaller than nl = |Sl|, l = 2, . . . ,m
since it is more difficult to obtain measurements of B1. Our objective is to estimate
the optimal ITR that assigns treatment A ∈ {−1,+1} to each subject based on
personal features X with the aim of maximizing the expected benefits.
3.3.2 Synergistic Self-learning
In the case of a single benefit outcome, say B, the existing seminal OWL (Zhao
et al., 2012) estimates an optimal decision rule D∗ by solving the following optimiza-
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ᵀXi + b) ≥ 1− ξi and ξi ≥ 0, i = 1, ..., n
(3.1)
where f(X) = ωᵀX + b is the decision rule over the space of linear functions, C
is the tuning parameter of SVM, and ξi = (1 − Aif(Xi))+ is the slack variable.
From (3.1) we see that the main difference between OWL and standard SVM is
that the former weights each slack variable ξi with a scaled personal clinical benefit
value Bi/P (Ai | Xi). We can generalize the approach to obtain a nonlinear decision
rule using a kernel function K : X × X → R via the theorem of the reproducing
kernel Hilbert space (RKHS) HK (Cortes and Vapnik , 1995). For simplicity, we focus
on linear decision rules in the following algorithm. But the method can be easily
extended to nonlinear decision rules with little effort.
OWL only works for a single outcome, which has to be extended to analyze data
with multiple outcomes. To address this technical need, we propose the following
algorithm.
Algorithm III.1. Suppose that we have one high-quality dataset S1 = {(B1i, Ai,Xi),
i = 1, . . . , n1} and multiple low-quality datasets Sl = {(Bli, Ai,Xi), i = 1, . . . , nl},
l ∈ L = {2, . . . ,m}, where n1 < nl and B1 is of higher clinical relevance than Bl. Let
p = P (A | X). We iterate the following steps. Refer to Figure 3.2 for the workflow
of the proposed SS-learning algorithm.
S1 Estimate an ITR by OWL using S1 of high quality and get the initial estimates




Sl of low qualities. Denote the predicted labels as y(0)li , i ∈ Sl, l ∈ L.
S2 The k-th (k ≥ 1) iteration runs through the following Steps 2.1-2.3.
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S2.1 Define an augmented training dataset S(k) = S1 ∪ S̃(k)2 ∪ · · · ∪ S̃
(k)
m , where
individuals in S̃(k)l , l ∈ L have their predicted labels from the previous
iteration k − 1, resulting in S̃(k)l = {(Bli, Ai, y
(k−1)
li ,Xi), i = 1, . . . , nl} =
Sl ∪ {y(k−1)li , i = 1, . . . , nl}, l ∈ L.


























ᵀXi + b) ≥ 1− ξi and ξi ≥ 0, i ∈ S1,
Ai(ω




ᵀXi + b) ≥ 1− ξ̌li and ξ̌li ≥ 0, i ∈ S̃(k)l , l ∈ L.
(3.2)
where λl ∈ [0, 1] is an additional tuning parameter that characterizes the
relative contribution of the predicted and observed information from S̃(k)l











ξ̌li, so to reduce the bias over the tuning of λl. Denote the
estimates of the parameters as (ω(k), b(k), ξ(k)) at iteration k. Also, the
predicted labels for S̃(k)l are updated as y
(k)
li , i ∈ S̃
(k)
l , l ∈ L.

































S3 The algorithm stops if |h(ω
(k),ξ(k))−h(ω(k−1),ξ(k−1))|
h(ω(k−1),ξ(k−1))
< ε for a pre-determined pre-
cision constant ε, say 10−4. The convergence values of (ω(k), b(k)) are de-
noted by (ω̂, b̂), and the predicted labels at convergence for S are denoted
as ŷi, i = 1, . . . , n.
Figure 3.2: Workflow of the proposed synergistic self-learning algorithm.









P (Ai|Xi) ξ̃li represents an OWL




P (A|X) ξ̌li represents a standard SVM
classification problem based on S̃(k)l , l ∈ L with the predicted labels y(k−1). During
every iteration, each case i in S̃(k)l , l ∈ L is associated with two pieces of information:
a) benefit Bli resulted from treatment Ai, and b) predicted label y
(k−1)
i that borrows
information from S1. The optimization problem (3.2) takes both into consideration,
where tuning parameter λl ∈ [0, 1], l ∈ L governs their relative importance. When
λl = 0, we ignore the contribution from observed benefit Bl, and think that it is com-
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pletely untrustworthy, and use the predicted labels only in optimization. In contrast,
when λl = 1, we believe that Bl has the same quality as B1, so to ignore the predicted
labels, and consequently treat the problem (3.2) as a standard OWL on the combined
data S1 ∪ S2 ∪ · · · ∪ Sm.
3.3.3 Algorithmic Convergence
We establish the algorithmic convergence of SS-learning in the following theorem
with the proof presented in Appendix E.
Theorem III.1. The SS-learning objective function h(ω(k), ξ(k)) at iteration k sat-
isfies the descending property over iterations, namely h(ω(k), ξ(k)) ≤ h(ω(k−1), ξ(k−1))
for k ≥ 2. The equality occurs when the algorithm converges.
3.3.4 Tuning Parameter Selection
To perform SS-learning, we need to choose the tuning parameters C and λ. Due
to a small sample size of the “good” data S1, the method of cross-validation does not
yield stable and reliable tuning results. We propose to choose the values of C and λ
at which the SSE of the predicted benefit values is minimized. This may be done by
performing a grid search of C and λ on the entire dataset S1 ∪ · · · ∪ Sm. We define










The individual predicted benefit value B̂li is obtained from the following regression
models,
Bl = φl(X, Af̂(X)) + εl, (3.5)
where φl(a, b) = gl(a) + βlb for some function gl(·), l = 1, . . . ,m, f̂(·) is the estimated
decision function as an output of SS-learning, and εl, l = 1, . . . ,m are error terms.
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In the simulation experiment described in Section 3.4 and the real data analysis
discussed in Section 3.5, we choose linear models for φl to predict benefit. More
general models like generalized additive model (GAM) can also be applied for φl (see
the simulation experiment described in Appendix G) when the association between
X and the benefit is assumed to be complicated and nonlinear.
3.4 Simulation Experiments
We ran multiple simulation experiments to validate the use of SS-learning in our
data analyses. Here we report one of such simulation experiments to illustrate the
finite sample performance of SS-learning in ITR derivation. More simulation results
are included in Appendix F-G. We designed the simulation with three data sources:
S1 contains high-quality benefit B1, S2 and S3 contain low-quality benefit B2 and B3,
respectively.
We randomly generated a 10-dimensional feature vector X = (X1, . . . , X10)
ᵀ ∈
R10 for each subject, where Xν
i.i.d∼ U(0, 1), ν = 1, . . . , 10. Treatment A ∈ {−1, 1} was
randomly allocated to subjects with P (A = 1 | X) = P (A = −1 | X) = 0.5. The
underlying true decision function f was specified as f(X) = 1 +X1 +X2 − 1.8X3 −
2.2X4. The observed benefit B1 was generated from a normal distribution with mean
µ1 = 0.01+0.02X4+3.0Af(X) and standard deviation σ1 = 0.1, the observed benefit
B2 was generated from a normal distribution with mean µ2 = 0.1+0.2X4+1.0Af(X)
and standard deviation σ2 = 0.5, while B3 was generated from a normal distribution
with mean µ3 = 0.1 + 0.2X4 + β3Af(X) and standard deviation σ3. Let the total
sample size n = n1 + n2 + n3, where n1 = |S1|, n2 = |S2| and n3 = |S3|. In order to
evaluate the performance of SS-learning under varying relevance of B1, B2 and B3, we
considered the following scenarios: (a) β3 ∈ {0.1, 0.5, 1.0, 3.0}, σ3 = 1.0, n1 = 20, n2 =
100, n3 = 380; (b) β3 = 0.5, σ3 ∈ {0.1, 0.5, 1.0, 2.0}, n1 = 20, n2 = 100, n3 = 380; (c)
β3 = 0.5, σ3 = 1.0, n1 ∈ {20, 100, 180, 250}, n2 = 100, n3 ∈ {380, 300, 220, 150}. In
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addition, an independent dataset of sample size 1000 with true labels by f(X) > 0 or
otherwise was generated for external validation. The optimization function was solved
using the linear kernel. We set tuning parameter C ∈ {1/128, 1/64, . . . , 1/2, 1} and
weighting parameter λ ∈ {0, 0.1, . . . , 0.9, 1.0} for parameter selection. Simple linear
regression with all the main effects of X was employed for the regression models
gl(X), l = 1, 2, 3 in parameter tuning. For each scenario, simulation was repeated for
200 times to draw summary statistics.
We compared four methods for their prediction accuracy on the training and
validation datasets: (M1) SS-learning with tuning according to the minimization of
SSE; (M2) oracle SS-learning with optimal tuning according to the highest prediction
accuracy on S = S1 ∪ S2 ∪ S3; (M3) OWL with 5-fold cross-validation based tuning
of C in SVM on S1 alone; (M4) OWL with 5-fold cross-validation based tuning of
C in SVM on S. M2 is regarded as the oracle method; the tuning of C and λ
through the prediction accuracy of S is infeasible in reality because we never know
the true underlying labels in S. Both M3 and M4 are based on 5-fold cross-validation
proposed in Zhao et al. (2012). Figure 3.3 shows the average prediction accuracy
of these four methods on the training and validation datasets. It is shown that the
oracle SS-learning M2 always gives the highest prediction accuracy. The M1 method,
which we can use in practice, gives a slightly lower prediction accuracy compared to
M2. The prediction accuracy given by M4 is constantly lower than M1 and M2. M3
always obtains the smallest prediction accuracy.
In addition, Table 3.2 lists the λ values tuned by method (3.4). Generally speak-
ing, the selected λ3 value increases with increasing β3 and decreases with increasing
σ3. This is fully expected since larger β3 and/or smaller σ3 lead to higher relevance
and better quality of B3. However, the change of λ3 along with different sample
size ratios is not clearly shown due to the complicated relative clinical relevance be-
tween B1, B2 and B3 represented by the relative sample sizes. The selected values
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Figure 3.3: Comparison of prediction accuracy on the training and validation datasets
by different methods under (a) varying β3, (b) varying σ3, (c) varying
n1/n.
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Table 3.2: Selected weighting values λ2 and λ3 (mean (sd)) based on SS-learning using
proposed tuning.
scenario λ2 λ3
β3 = 0.1 0.50 (0.37) 0.40 (0.32)
β3 = 0.5 0.55 (0.38) 0.70 (0.28)
β3 = 1.0 0.52 (0.37) 0.80 (0.23)
β3 = 3.0 0.51 (0.38) 0.79 (0.22)
σ3 = 0.1 0.45 (0.36) 0.90 (0.17)
σ3 = 0.5 0.53 (0.38) 0.81 (0.22)
σ3 = 1.0 0.55 (0.37) 0.68 (0.30)
σ3 = 2.0 0.53 (0.37) 0.51 (0.30)
n1/n = 0.04 0.56 (0.38) 0.66 (0.29)
n1/n = 0.20 0.61 (0.37) 0.64 (0.34)
n1/n = 0.36 0.51 (0.39) 0.64 (0.37)
n1/n = 0.50 0.58 (0.41) 0.64 (0.38)
of λ2 are stable over the changes of β3, σ3 and n1/n, which is fully expected since
the change of B1 and B3 barely changes the relative importance of B2. The demon-
strated sensitivity to varying clinical relevance and quality of auxiliary data signifies
the proposed tuning method (3.4) as a satisfactory and reliable tuning procedure.
We then calculated the estimated value functions of B1, B2 and B3. The values are
listed in Table 3.3-3.5. It is shown that M2 always gives the highest estimated value
function as expected. But M1 gives higher estimated value functions than the OWL
methods M3 and M4, indicating that the estimated ITR derived from M1 will lead
to the highest clinical benefit if it were implemented for the whole study population
in the future. Additional simulation results about the algorithmic convergence, the
SSE values and the computation time based on methods M1-M4, as well as another
nonlinear simulation experiment, are included in Appendix F-G.
3.5 Analysis of Calcium Supplementation Trial
In this section, we present the data analysis for the ELEMENT calcium supple-
mentation trial using the SS-learning method. As pointed in Section 3.1, the central
45
Table 3.3: Estimated value function of B1 (mean (sd)) based on SS-learning with
proposed tuning, SS-learning with oracle tuning, OWL on S1, and OWL
on S = S1 ∪ S2 ∪ S3.
SS-learning (tune) SS-learning (oracle) OWL on S1 OWL on S
β3 = 0.1 6.71 (1.34) 6.79 (1.26) 6.12 (1.23) 6.13 (1.47)
β3 = 0.5 7.06 (1.28) 7.04 (1.29) 6.12 (1.23) 6.75 (1.37)
β3 = 1.0 7.28 (1.31) 7.28 (1.26) 6.12 (1.23) 7.18 (1.28)
β3 = 3.0 7.38 (1.38) 7.42 (1.31) 6.12 (1.23) 7.36 (1.28)
σ3 = 0.1 7.22 (1.31) 7.24 (1.22) 6.12 (1.23) 6.90 (1.35)
σ3 = 0.5 7.17 (1.23) 7.19 (1.24) 6.12 (1.23) 6.85 (1.35)
σ3 = 1.0 7.05 (1.26) 7.05 (1.28) 6.12 (1.23) 6.80 (1.36)
σ3 = 2.0 6.84 (1.43) 6.88 (1.31) 6.12 (1.23) 6.55 (1.40)
n1/n = 0.04 7.02 (1.35) 7.08 (1.23) 6.12 (1.23) 6.77 (1.40)
n1/n = 0.20 8.65 (0.96) 8.66 (0.96) 8.25 (1.00) 8.52 (1.00)
n1/n = 0.36 9.22 (0.82) 9.23 (0.81) 9.04 (0.83) 9.13 (0.83)
n1/n = 0.50 9.51 (0.72) 9.51 (0.72) 9.39 (0.71) 9.43 (0.72)
Table 3.4: Estimated value function of B2 (mean (sd)) based on SS-learning with
proposed tuning, SS-learning with oracle tuning, OWL on S1, and OWL
on S = S1 ∪ S2 ∪ S3.
SS-learning (tune) SS-learning (oracle) OWL on S1 OWL on S
β3 = 0.1 1.34 (0.24) 1.35 (0.23) 1.31 (0.23) 1.33 (0.23)
β3 = 0.5 1.36 (0.23) 1.36 (0.23) 1.31 (0.23) 1.35 (0.23)
β3 = 1.0 1.36 (0.23) 1.37 (0.23) 1.31 (0.23) 1.36 (0.24)
β3 = 3.0 1.36 (0.25) 1.37 (0.23) 1.31 (0.23) 1.36 (0.23)
σ3 = 0.1 1.36 (0.26) 1.37 (0.24) 1.31 (0.23) 1.36 (0.23)
σ3 = 0.5 1.36 (0.24) 1.36 (0.23) 1.31 (0.23) 1.36 (0.23)
σ3 = 1.0 1.36 (0.24) 1.36 (0.23) 1.31 (0.23) 1.35 (0.23)
σ3 = 2.0 1.34 (0.26) 1.36 (0.23) 1.31 (0.23) 1.34 (0.23)
n1/n = 0.04 1.35 (0.25) 1.36 (0.24) 1.31 (0.23) 1.35 (0.23)
n1/n = 0.20 1.32 (0.22) 1.32 (0.23) 1.31 (0.23) 1.32 (0.23)
n1/n = 0.36 1.36 (0.23) 1.36 (0.22) 1.35 (0.23) 1.35 (0.23)
n1/n = 0.50 1.36 (0.24) 1.37 (0.24) 1.36 (0.24) 1.36 (0.24)
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Table 3.5: Estimated value function of B3 (mean (sd)) based on SS-learning with
proposed tuning, SS-learning with oracle tuning, OWL on S1, and OWL
on S = S1 ∪ S2 ∪ S3.
SS-learning (tune) SS-learning (oracle) OWL on S1 OWL on S
β3 = 0.1 3.06 (0.38) 3.06 (0.38) 3.01 (0.39) 3.05 (0.38)
β3 = 0.5 3.53 (0.42) 3.53 (0.42) 3.31 (0.43) 3.46 (0.43)
β3 = 1.0 4.56 (0.45) 4.56 (0.44) 4.10 (0.52) 4.50 (0.44)
β3 = 3.0 9.90 (1.05) 9.96 (0.78) 8.49 (1.01) 9.85 (0.80)
σ3 = 0.1 1.60 (0.17) 1.61 (0.13) 1.37 (0.17) 1.53 (0.17)
σ3 = 0.5 2.30 (0.24) 2.30 (0.24) 2.07 (0.27) 2.23 (0.27)
σ3 = 1.0 3.54 (0.38) 3.54 (0.38) 3.33 (0.41) 3.48 (0.39)
σ3 = 2.0 6.28 (0.86) 6.30 (0.72) 6.11 (0.73) 6.23 (0.71)
n1/n = 0.04 3.57 (0.45) 3.59 (0.38) 3.37 (0.40) 3.52 (0.39)
n1/n = 0.20 3.49 (0.43) 3.49 (0.43) 3.41 (0.44) 3.46 (0.43)
n1/n = 0.36 3.41 (0.44) 3.41 (0.44) 3.38 (0.44) 3.40 (0.44)
n1/n = 0.50 3.25 (0.48) 3.26 (0.48) 3.23 (0.48) 3.24 (0.47)
objective of our analysis is to derive an ITR for pregnant women in taking calcium
supplementation to maximize the reduction of fetal blood lead concentration at birth.
The primary outcome B1 is the cord blood lead concentration, the second outcome
B2 is the blood lead concentration of infant at 3-month age, and the third outcome
is the maternal blood lead concentration at the third trimester. SS-learning is based
on an ordering benefit value, with the larger magnitude of benefits, the more clinical
desirable outcome. To fit in this framework, we reversed the direction of lead concen-
tration by a transformation, max
i
(Bi) − Bi, i = 1, . . . , n. After deleting observations
with missing data, 59 participants have cord blood lead measurements (37 taking
calcium supplement; 22 taking placebo), 190 participants have infant 3-month blood
lead concentration measurements (95 taking calcium supplement; 95 taking placebo),
and 116 participants have maternal blood lead concentration measurements at the
third trimester (51 taking calcium supplement; 65 taking placebo). We performed
an intention-to-treat analysis under the missing completely at random (MCAR) as-
sumption, since the attrition of measurements was due mainly to the logistic issues
of biosample collection not related to lead exposure. Since the number of subjects
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Figure 3.4: Evaluation of predictor balance. (a) Distributional balance of propensity
score before and after weighting. (b) predictor balance before and after
weighting illustrated by the absolute standardized mean differences. The
thresholds -0.1 and 0.1 are shown as the vertical dashed lines.
with lead concentration measurements from the two arms are not fully balanced (as
is shown in Table 3.1), the propensity score P (A | X) was estimated by logistic
regression based on all the major effects of the predictors.
After weighting the observations by the estimated propensity score, we evaluated
the balance of the propensity score by plotting the group-specific distributions and
the balance of the predictors using the absolute standardized mean differences (see
Figure 3.4). It is shown that predictor balance has been met within a threshold of
0.1, and that balance has improved after weighting for all the predictors, as well as
for the propensity score.
We then came to the major objective to derive an ITR for calcium supplementation
to pregnant women based on the predictors. We performed: (i) a standard OWL
analysis on the dataset S1 with B1 and got the estimated decision rule f̂1; (ii) a
standard OWL analysis on the augmented training data by including S2 with B2 and
S3 with B3, and naively ignored the differences of clinical relevance (i.e. λ2 = λ3 = 1)
and got the estimated decision rule f̂2; (iii) the proposed SS-learning on the whole
dataset in which we took into account differences between B1, B2 and B3 in terms of
their clinical relevance to the underlying health benefit and got the estimated decision
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rule f̂3. Linear kernel was used for solving the optimization function (see Algorithm
III.1) of SS-learning and linear regressions were applied for parameter tuning (see
Section 3.3.3). The resulting estimated decision rules are given as
f̂1 =0.02 + 0.47age− 0.03weight + 0.03school + 0.72married + 0.19parity
− 0.66HgB− 0.33Ca + 0.03fiber− 0.10Fe + 0.48Zn + 0.09VC− 0.01PBM
f̂2 =− 0.20 + 0.18age− 0.12weight + 0.22school− 0.05married + 0.03parity
− 0.05HgB− 0.33Ca + 0.61fiber + 0.04Fe + 0.05Zn− 0.04VC− 0.31PBM
f̂3 =− 0.33 + 0.57age− 0.17weight− 0.08school + 0.60married + 0.11parity
+ 0.26HgB− 0.81Ca + 0.67fiber + 0.17Fe + 0.21Zn + 0.03VC− 0.57PBM
Using the proposed parameter tuning procedure, we obtained λ2 = 0.8 and
λ3 = 0.3 in the estimation of f̂3, indicating that infant 3-month blood lead concen-
tration has slightly lower clinical relevance, while maternal blood lead concentration
at the third trimester has much lower clinical relevance, than cord blood lead con-
centration when used to derive the ITR. Applying the estimated decision rules on
each subject, we would allocate a pregnant woman to take the calcium supplement
if f̂q > 0, q = 1, 2, 3; otherwise, she does not need to do so because of no benefit.
Among the total 365 individuals, f̂1, f̂2 and f̂3 assigns 277, 130, and 210 subjects
to take the calcium supplement, respectively. Comparing the treatment assignment
results between complete randomization A and the estimated decision rule f̂3 by SS-
learning, we found a significantly different reallocation (McNemar test p-value 0.036)
(see Table 3.6), indicating that the difference in treatment allocation does not arise
by accident.
The SSE values given by f̂1, f̂2 and f̂3 are 1365.6, 1355.2 and 1342.2, indicating
that the linear regressions derived from f̂3 give the best prediction of the benefit
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Table 3.6: Treatment assignment comparison between complete randomization and
f̂3 estimated by SS-learning.
f̂4
placebo calcium total
randomization placebo 86 96 182
calcium 69 114 183
total 155 210 365
Table 3.7: Estimated value functions of B1, B2 and B3 based on A, the estimated ITR
f̂1, f̂2, f̂3 for the analysis of the calcium supplementation trial.
V̂ (B1) V̂ (B2) V̂ (B3)
A 8.80 8.86 10.92
f̂1 8.79 8.98 11.37
f̂2 8.70 8.85 10.97
f̂3 8.97 8.98 11.45
values. In order to illustrate the performance of f̂1, f̂2 and f̂3 in reducing the maternal
lead exposure to infant, we also calculated the estimated value functions of B1, B2
and B3 as E∗n{I(A = D(X))B/P (A | X)}/E∗n{I(A = D(X))/P (A | X)} (Murphy
et al., 2001), where E∗n denotes the empirical average. The estimated value functions
based on complete treatment randomization and the three estimated decision rules are
summarized in Table 3.7. It shows that f̂3 gives the highest estimated value functions
for B1, B2 and B3, suggesting the largest reduction in fetal blood lead instead of f̂1
or f̂2 when they were implemented for the whole study population. This indicates
that the inclusion of B2 and B3 by taking the heterogeneous clinical relevance into
account has improved the estimated ITR in terms of the estimated benefit values.
Checking the demographic and baseline predictors of the individuals (see Ta-
ble 3.8), we found that subjects assigned to take calcium supplementation by f̂3 have
a significantly older age in agreement with the positive coefficient of predictor age
in f̂3. That is, older pregnant women are more likely to benefit from calcium sup-
plement. In addition, subjects assigned to taking calcium supplement by f̂3 have a
significantly higher proportion of marriage, a significantly larger hrp parity, a signif-
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Table 3.8: Summary statistics of the predictors based on treatment allocation accord-
ing to f̂3. Mean (sd) and percentage values are shown for the numeric and
categorical predictors respectively. p-values are obtained from t-test and
chi-aquare test.
Predictor Calcium Placebo p-value
age 28.5 (5.2) 23.7 (4.9) < 2.20× 10−16
weight 62.4 (10.7) 61.3 (10.2) 2.89× 10−1
school 11.0 (3.1) 10.4 (2.8) 5.56× 10−2
married 0.771 0.581 1.55× 10−4
hrp 2.3 (1.0) 1.9 (1.0) 1.56× 10−3
HgB 13.4 (0.8) 13.0 (1.2) 3.36× 10−4
Ca 10.4 (4.8) 11.6 (5.6) 2.55× 10−2
fiber 26.3 (9.6) 19.8 (8.0) 8.89× 10−12
Fe 14.4 (5.9) 11.7 (5.2) 7.53× 10−6
Zn 9.8 (3.4) 9.0 (3.8) 3.13× 10−2
VC 192.1 (90.5) 150.9 (73.9) 2.61× 10−6
PBM 4.2 (2.7) 6.1 (3.6) 1.08× 10−7
icantly higher HgB concentration, a significantly lower dietary intake of calcium, a
significantly higher dietary intake of fiber, Fe, Zn and vitamin C, and a significantly
lower baseline blood lead concentration. These are also aligned with their coefficients
in f̂3, indicating that pregnant women of being married, being pregnant for more
times, having higher HgB concentration, having lower calcium intake from food, hav-
ing higher dietary intake of fiber, Fe, Zn, and vitamin C and having lower level of
baseline blood lead tend to benefit from calcium supplement. Interestingly, subjects
assigned to the calcium supplement by f̂3 have a lower calcium intake from food
(1037.3 (482.5) versus 1163.5 (563.7)), meaning that participants who have enough
dietary calcium do not need to take calcium supplement. This finding is clinically
appealing. However, no significant differences were identified for weight and years in
school between the two allocated groups.
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3.6 Concluding Remarks
In this chapter, we derived an ITR for pregnant women in the take of daily cal-
cium supplementation to maximize the reduction of maternal lead exposure to in-
fants during pregnancy using SS-learning based on the ELEMENT calcium trial.
The major difficulty in analyzing the data lies in the fact that we have to integrate
multiple outcomes of interest with heterogeneous clinical relevance and sample sizes
in the derivation of ITR, in order to achieve high reproducibility and robustness of
the derived ITR. SS-learning solves this problem based on a weighted self-learning
paradigm with characterization of the relative contributions of respectively low- and
high-quality data sources. SS-learning is particularly appealing in ITR derivation us-
ing real clinical trial data when measuring high quality data of high clinical relevance
is often expensive, resulting in a small sample size, while more data sources of much
larger sample sizes but likely of low clinical relevance are available. Simulation stud-
ies in Section 3.4 show that our method converges fast and outperforms the existing
decision rule estimation method OWL.
To our knowledge, it is the first time such an ITR in assigning calcium supplemen-
tation to pregnant women is established. The results reveal that the auxiliary data
sources of infant 3-month blood lead concentration and maternal blood lead concen-
tration at the third trimester have a lower clinical relevance than the gold cord blood
lead concentration in the derivation of ITR for calcium supplementation allocation.
But the integration of these secondary outcomes of interest do improve the derived
ITR with respect to the expected lead reduction compared to the ITR estimated by
the primary outcome alone or by naively treating the different outcomes as having
equal clinical relevance. The resulting rule can increase lead exposure reduction in
uterus. Clinically, it is of great importance to improve a decision rule given for further
reduction of blood lead concentration, which has been accomplished by our analysis
based on the proposed SS-learning method. In addition to the different clinical rele-
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vance we have characterized for the three outcomes used for ITR estimation, we also
identified the variables that play significant roles in allocating calcium supplementa-
tion to pregnant women. Interestingly, dietary intake of fiber, Fe, Zn and vitamin C
will influence the assignment of calcium supplement, indicating a complex network of
interactions involving different nutrient contents. This suggests us to consider more
comprehensively when making recommendations for individuals to take nutritional
supplements.
In this article, we employed linear kernel to derive the decision rule f̂3 using SS-
learning to easily illustrate the derived ITR. Nonlinear-kernels can also be applied to
derive more complicated decision rules. Another simulation experiment included in
the online Supplementary Materials shows the performance of radial basis function
(RBF) kernel in the establishment of ITR. Different regression models are also com-
pared to get the tuning parameters. In the application of SS-learning, selection of
kernel functions and parameter tuning models are of great importance to guarantee
good performance of the derived ITR. Since the linear ITR derived by SS-learning
already gives higher expected benefits compared to the decision rules estimated using
traditional OWL for this ELEMENT calcium supplementation trial, we did not try
nonlinear kernels, which can be a further direction for future analysis. Additional
future research can be devoted to extending this methodology to clinical trial with
multiple treatment arms, to situations where there are categorical outcomes or time-
to-event outcomes, and to dynamic treatment regimes. Moreover, we may alleviate
the computing burden of grid search in the tuning when the number of auxiliary
datasets is large by grouping auxiliary datasets with similar quality and relevance,
so to use the same λ value for each group, or by performing target search of λ value
within a certain smaller range.
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CHAPTER IV
Longitudinal Self-Learning of Individualized
Treatment Rules with Missing Data
4.1 Introduction
This chapter presents an exemplary applied statistics contribution to the emerg-
ing field of precision nutrition. As is mentioned in Chapter III, Barker’s DOHaD
hypothesis postulates a key conceptual paradigm for effects of perinatal environment
on the future health of offspring. We are still interested in controlling the maternal
lead exposure to infants, since a vast literature has unveiled that excessive exposure
to lead is detrimental on children’s neurobehavioral and cognitive development (Chen
et al., 2005; Hornung et al., 2009; Wasserman et al., 2003; Téllez-Rojo et al., 2006b;
Hu et al., 2006; Braun et al., 2012). As is introduced in Chapter III, reducing the
amount of lead released into maternal blood circulation during pregnancy is a sig-
nificant preventive measure to minimize lead exposure to children, as prenatal lead
exposure by fetus comes solely from mother. Clinically, blood lead control may be
achieved by calcium.
In this study of precision nutrition, we are interested in establishing an individu-
alized treatment rule (ITR) that can be tailored to pregnant women in taking daily
calcium supplement with the aim to reduce lead exposure to children of 3-years old.
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Not all pregnant women will have a long-term benefit from taking calcium supple-
mentation, which may due to two major reasons: one is that some pregnant women
already have enough calcium intake from their dietary food, and the other is that too
high blood calcium may increase the risk of miscarriage (Norman et al., 2009). The
derivation of such an ITR usually targets at the maximization of the expected out-
come. In this chapter, we still focus on the calcium supplementation trial from the
Early Life Exposure in Mexico to ENvironmental Toxicants (ELEMENT) Project.
But different from that in Chapter III, in particular, the endpoint outcome of inter-
est in this analysis is blood lead concentration for children (PBC; ”PB” represents
lead and ”C” represents children) at 36-month of age. This longitudinal trial collects
repeated measurements of PBC values at month 3, 6, 12, 18, 24, 30 and 36. We treat
the outcome measured at month 36 (denoted by PBC36) as the primary endpoint for
ITR derivation. Due to intermittent missing data or dropouts, the observations of
the PBC36 are incomplete (36.7% missingness), leading to the sample size attrition if
only the endpoint outcome is used. Consequently, both reliability and reproducibility
of the resulting ITR would be compromised. Therefore, one natural solution is to uti-
lize longitudinal data of blood concentration prior to PBC36 to construct ITR, where
a certain temporal weighting scheme is specified to reflect their clinical relevance to
the endpoint outcome.
Statistical methodologies for estimating decision functions in the field of preci-
sion medicine are abundant, such as outcome weighted learning (OWL) (Zhao et al.,
2012). Unfortunately, all the current learning methods are applicable only for a
one-dimensional cross-sectional outcome related to health benefit. It lacks suitable
methods in the literature that utilize temporally correlated outcomes and handle
missing data in both estimation and optimization of ITRs. To analyze the longitu-
dinal calcium supplementation trial, we extend the SS-learning method proposed in
Chapter III to longitudinal self-learning (LS-learning), which is flexible to not only
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incorporate longitudinal outcomes but also to handle incomplete data in ITR deriva-
tion. LS-learning works in a weighted self-learning paradigm via an effective training
data augmentation scheme, which is built upon the assumption that the relevance
of longitudinal outcomes increases over time towards the primary endpoint. More-
over, estimated subgroup labels learned from longitudinal outcomes measured prior
to the primary endpoint are iteratively calibrated with those labels determined by
the endpoint. Same as that for SS-learning, the relative contributions from longi-
tudinal outcomes are tuned by minimizing the sum of squared errors (SSE) of the
predicted treatment benefits. To handle missing data, we follow the idea of pattern
mixture model (Little, 2008) that stratifies subjects into subgroups according to their
missing data patterns. To deal with potential computational burden in tuning pa-
rameter selection as is discussed in Section 3.6, we adopt a scalable tuning procedure
incorporating the nature of longitudinal data collection. Meanwhile, using extensive
simulation experiments, we illustrate and confirm that the LS-learning algorithm can
numerically achieve both high classification rate for treatment subgroups and high
computational efficiency.
We apply LS-learning to derive an ITR in the longitudinal calcium supplemen-
tation trial, where we find that LS-learning would produce the largest benefit in
reducing children’s exposure to blood lead concentration at 36 months of age if the
resulting ITR were implemented for the whole study population of pregnant women,
in comparison to other ITRs derived from standard OWL. This improvement is of
clinical importance and is achieved by the means of longitudinal data augmentation
in our analysis, which showcases an exemplary approach to deliver better solutions
in precision nutrition. Several predictors that play an important role in forming the
ITR are also identified. Interestingly, dietary intake of fiber, Fe, Zn and vitamin C
will influence the assignment of calcium supplement, indicating a complex group of
interactions involving different nutrient contents.
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The remainder of the chapter is organized as follows. Section 4.2 introduces
the longitudinal calcium supplementation trial. Section 4.3 presents the LS-learning
approach, including its systematic parameter tuning method. Section 4.4 concerns
the evaluation of LS-learning through simulation experiments. Data analysis for
the longitudinal calcium trial is detailed in Section 4.5. Section 4.6 contains some
concluding remarks.
4.2 Application: Longitudinal Calcium Supplementation Trial
In the ELEMENT Project, one of the major objectives is to assess how environ-
mental exposures, such as heavy metals or endocrine disrupting chemicals (EDCs),
affect the health outcomes of pregnant women and their children (Téllez-Rojo et al.,
2004; Zhang et al., 2012). This chapter still focuses on the calcium supplementation
trial conducted in the third cohort of the ELEMENT study.
As is introduced in Section 3.2, this clinical trial contains a total of 670 women
who were recruited at their first trimester of pregnancy during 2001 to 2003 in Mexico
City, with 334 mothers randomized to receive a daily dose of 1200 mg calcium sup-
plement and 336 randomized to receive placebo (Zhang et al., 2012). These mothers
are followed during both pre- and post-natal pregnancy. Demographic information
and biological samples from both mothers and children (i.e. mother-child pairs) are
collected for clinical measurements. The primary outcome of interest is child’s blood
lead concentration (PBC) at 36-month of age, denoted by PBC36, which is an end-
point of clinical importance due to its known influence on children neurobehavioral
development (Wasserman et al., 1998; Mendelsohn et al., 1998). In addition to this
primary PBC36 outcome, six repeated measurements of PBC at month 3, 6, 12, 18,
24, and 30 are collected during the followup visits as part of the longitudinal study,
which for convenience are denoted by PBC3, PBC6 and so on. Figure 4.2 displays the
longitudinal trajectories of PBC values in the calcium supplementation and placebo
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Figure 4.1: Missing of PBC values at different visit times. (a) Percentage of missing
and observed PBC values at month 3, 6, 12, 18, 24, 30, and 36. (b)
Stratification of mother-child pairs into different missing patterns based
on individual endpoints.
group. Instead of deleting mother-child pairs with missing measurement of PBC36
(37.6% missingness), we intend to borrow longitudinal PBC values measured prior
to month 36 into ITR derivation, resulting in an improved ITR by recovering data
attrition. We propose to stratify mother-child pairs in terms of their missing data
patterns, leading to subgroups with specific last available observation, which is taken
as a surrogate or an approximate endpoint of lead exposure measured at an earlier
time point than month 36. Figure 4.1 shows the percentage of missingness for different
PBC values and the stratification of subgroups with different individual endpoints.
For example, if a child has PBC observed at month 3, 12, 18, and 30, the last available
PBC observation of this individual, namely PBC30, is taken as a surrogate endpoint
which will be used in ITR derivation.
We choose the same group pf baseline predictors as those in Chapter III to be used
for ITR derivation. Summary statistics of these predictors in the calcium supplemen-
tation and placebo group, as well as the differences of their distributions characterized
by t-test or chi-square test are listed in Table 4.1. The final training dataset excludes
293 mother-child pairs that have missing data in the baseline predictors. The data
we received from the ELEMENT group is the one with all baseline predictors fully
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Figure 4.2: Trajectories of PBC values in the calcium supplementation and placebo
group. The black summary line is fitted by the generalized additive model
(GAM).
Table 4.1: Summary statistics of the predictors included in ITR derivation. Mean
(sd) and percentage are shown, where p-values are obtained from t-test
and chi-square test for numeric and categorical variables, respectively.
Predictor Calcium Placebo p-value
age 26.9 (5.7) 25.9 (5.4) 0.071
weight 62.0 (11.3) 61.6 (9.6) 0.717
school 10.8 (2.9) 10.7 (2.9) 0.600
married 0.695 0.677 0.802
hrp parity 2.1 (1.0) 2.1 (1.1) 0.867
HgB 13.2 (1.0) 13.2 (1.0) 0.800
Ca 11.2 (4.9) 10.8 (5.5) 0.493
fiber 24.4 (10.0) 22.8 (9.0) 0.125
Fe 13.7 (5.9) 12.9 (5.5) 0.223
Zn 9.8 (3.5) 9.3 (3.6) 0.173
VC 178.1 (92.1) 172.7 (80.4) 0.548
PBM 4.7 (2.7) 5.3 (3.7) 0.070
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observed. In addition, we further exclude one mother-child pair with all longitudinal
PBC values missing at the 7 visits.
4.3 Formulation of LS-learning
This section presents the details of longitudinal self-learning (LS-learning) that
will be used to derive an ITR using longitudinal data with missing outcomes. This
LS-learning helps us yield a novel ITR from the calcium supplementation trial to
reduce continuous lead exposure for children at 36-month of age.
4.3.1 Notation
Denote the longitudinal data S = {(Xi, Ai, tij, Bij, Rij), i = 1, . . . , n, j = 0, . . . ,mi}
collected from a two-armed randomized clinical trial (i.e. the longitudinal calcium
supplementation trial). Let i and j denote the index of subject (i.e. mother-child
pair i ) and followup visit j, respectively. These two indices i or j may be sup-
pressed when there is no confusion. In the rest of this chapter, “subject” represents
“mother” when it comes to the measurements of baseline predictors, or represents
“child” when it refers to the measurements of outcomes (i.e. the longitudinal PBC
values), or represents “mother-child” pair when data from both are in the use. There
is a total of n mother-child pairs and mi repeated measurements for subject i, and
j = 0 corresponds to the baseline visit prior to treatment randomization. For ease of
exposition, we consider a longitudinal trial with outcomes measured at common visit
times j = 0, . . . ,m, where j = m stands for the time for the measurement of primary
endpoint (i.e. PBC36, which is the PBC value at the 36-month visit when j = 7).
Consequently, visit times tij ≡ tj, j = 1, . . . ,m. Assigned treatment at the beginning
of the trial is denoted as Ai ∈ A = {−1, 1}, where Ai = 1 represents the new treat-
ment (i.e. calcium supplementation) and Ai = −1 represents placebo. Xi ∈ Rd is
a d-dimensional vector of predictors measured at baseline. The outcome of interest,
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denoted by Bij, is repeatedly measured at time tj for subject i. It is assumed that the
larger value of B the higher benefit to health. Specifically, according to the clinical
study, it is the outcome Bm that serves as the primary outcome to be used for ITR
derivation. All the other intermittent measurements, B1, . . . , Bm−1, are treated as
surrogate outcomes providing relevant and auxiliary information of benefit trajectory
reaching the endpoint Bm. Due to dropouts or other reasons, some of the individuals
in the trial are not measured at the final visit tm, resulting in missing data of the
primary endpoint Bm. For those subjects that do not complete the trial, instead of
deleting them from the analysis, certain surrogate endpoints will be chosen so that
they can remain in our ITR derivation. Let Rij ∈ {0, 1} denote the missingness of
outcome Bij, with Rij = 1 representing the missing value and Rij = 0 representing
the observed value.
4.3.2 Longitudinal Self-learning
As is discussed in Chapter III, SS-learning is proposed to overcome the limita-
tion that OWL only works for a single cross-sectional outcome. In this chapter,
we further propose LS-learning, which is an extension to SS-learning that addresses
the methodological need in ITR deviation with longitudinal outcomes. We pro-
ceed this extension in the setting of multiple training datasets, obtained specifically
from stratification on missing-data patterns in a clinical trial with dropouts. Denote
Sm = {(Xi, Ai, tm, Bim), i = 1, . . . , nm} as the subset of completers, namely the sub-
jects who have measurements Bm. All the other subjects i ∈ S̄m have their individual
surrogate endpoints, depending on specific available last observations over dropout
time points. This results in m − 1 subsets Sj = {(Xi, Ai, tj, Bij), i = 1, . . . , nj}, j ∈
J = {1, . . . ,m− 1}, each corresponding to one stratum. Obviously, some of subsets
may be empty; for example, all of them are empty sets if all subjects complete the
trial. To estimate ITR, we plan to apply LS-learning that integrates the subset of
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completers Bim, i ∈ Sm with all the other subsets Bij, i ∈ Sj, j ∈ J in a systematic
way. The proposed LS-learning algorithm in a generic fashion is given as follows.
Algorithm IV.1. Suppose we have a primary dataset Sm = {(Xi, Ai, tm, Bim), i =
1, . . . , nm} with the outcome taken at tm and multiple auxiliary datasets Sj = {(Xi, Ai,
tj, Bij), i = 1, . . . , nj}, j ∈ J = {1, . . . ,m − 1} with the outcome taken prior to tm.
Assume that Bm is of higher quality than Bj in ITR derivation. Let pi = P (Ai |Xi)
be the propensity score. We iterate the following steps.
S1 Estimate ITR by OWL using Sm and get the initial estimates (ω(0), b(0), ξ(0)).
Then predict labels for subjects in
m−1⋃
j=1
Sj. Denote the predicted labels as y(0)ij , i ∈
Sj, j ∈ J .
S2 The k-th (k ≥ 1) iteration runs through the following steps S2.1-S2.3.
S2.1 Define an augmented training dataset S(k) = Sm∪ S̃(k)1 ∪ · · ·∪ S̃
(k)
m−1, where
individuals in S̃(k)j have their predicted labels from the previous iteration
k − 1, resulting in S̃(k)j = {(Xi, Ai, tj, Bij, y
(k−1)
ij ), i = 1, . . . , nj} = Sj ∪
{y(k−1)ij , i = 1, . . . , nj}, j ∈ J .

























ᵀXi + b) ≥ 1− ξi and ξi ≥ 0, i ∈ Sm,
Ai(ω




ᵀXi + b) ≥ 1− ξ̌ij and ξ̌ij ≥ 0, i ∈ S̃(k)j , j ∈ J .
(4.1)
where λj ∈ [0, 1] is an additional tuning parameter that characterizes the
relative contribution of the predicted and observed information from S̃(k)j .
τBj is a summary statistic (e.g. sample mean) of
Bij
pi
that is added as the
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so to reduce the bias over the tuning of λj. Denote the estimates of the
parameters as (ω(k), b(k), ξ(k)) at iteration k. Also, the predicted labels for
S̃(k)j are updated as y
(k)
ij , i ∈ S̃
(k)
j , j ∈ J .






























S3 The algorithm stops if |h(ω
(k),ξ(k))−h(ω(k−1),ξ(k−1))|
h(ω(k−1),ξ(k−1))
< ε for a pre-determined pre-
cision constant ε, say 10−4. The convergence values of (ω(k), b(k)) are denoted
by (ω̂, b̂), and the predicted labels at convergence for the whole training data
S are denoted as ŷi, i = 1, . . . , n.
The proposed Algorithm IV.1 is similar to Algorithm III.1 of SS-learning in Chap-
ter III. The major difference lies in the primary benefit outcome used for ITR deriva-
tion, which is the primary endpoint outcome Bm for LS-learning and the most high-
quality benefit outcome B1 in SS-learning. Meanwhile, LS-learning stratifies subjects
into subgroups with different individual endpoint outcomes according to their missing
data patterns, which is a procedure that is not employed in SS-learning.
4.3.3 Scaled Tuning Scheme
To perform LS-learning, we need to determine the tuning parameters C and
λ = {λj, j = 1, . . . ,m − 1}. As is proposed in Chapter III for SS-learning, pa-
rameter selection may be done through a grid search of C and λ on the entire dataset
S according to the minimization of the sum of squared errors (SSE) for the pre-
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predicted benefit value B̂ij is obtained from the stratum-specific regression model
Bj = φj(X, s(tj), Af̂(X)) + εj, with φj(a, b, c) = gj(a) + hj(b) + βjc for some func-
tion gj(·) and hj(·). f̂(·) is the estimated decision function via LS-learning and εj is
the error term. Multiple linear regression model or more flexible models such as the
generalized additive model (GAM) may be invoked to build the prediction rule φj(·).
In the simulation experiment described in Section 4.4, as well as the calcium trial
analysis discussed in Section 4.5, we choose GAM for φj to predict the longitudinal
benefit outcomes.
Each auxiliary dataset Sj will introduce a λj to tune, and the strategy of greedy
search proposed for SS-learning may make parameter tuning computationally expen-
sive and time consuming. To alleviate this computational burden, we propose a scaled
tuning method that specifies λj as a function of the standardized time t̃j = tj/tm,
i.e. λj = ψ(t̃j | θ) with certain parameter θ. The rationale of this systematic tuning
stems from that the relevant quality of Bj decays when time of current measurement
moves away from the time tm of the primary endpoint. As a result, this tuning pro-
cedure has fewer parameters to be tuned. Various ψ(·) functions can be specified
according to some preliminary knowledge of the underlying longitudinal relationship
between time and the relative quality of outcomes. Some examples of ψ(·) are given
as follows, and their time-course relevance to the endpoint are shown in Figure 4.3:
1. (Linear) ψ(t̃j | θ) = (1− θ) + θt̃j, θ ∈ [0, 1].
2. (Exponential) ψ(t̃j | θ) = θ1eθ2 t̃j , θ1 ∈ (0, 1], θ1eθ2 = 1.
3. (Polynomial) ψ(t̃j | θ) = θ1t̃2j + θ2t̃j + θ3, θ3 ∈ [0, 1], θ1 + θ2 + θ3 = 1.
To make a choice between different ψ(·), cross validation may be employed ac-
cording to the maximization of the estimated value function, defined as E∗n[I(A =
D(X))B/P (A | X)]/E∗n[I(A = D(X))/P (A | X)] (Murphy et al., 2001), where E∗n
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Figure 4.3: Change of tuning parameter λj according to standardized time t̃j.




This section reports one simulation experiment to illustrate the finite sample per-
formance of scaled-tuning LS-learning in ITR derivation using longitudinal trial data
with missing information. We randomly generated a 10-dimensional feature vector
X = (X1, . . . , X10)
ᵀ ∈ R10 for each subject, with each feature Xν ∼ U(0, 1), ν =
1, . . . , 10 and Corr(Xν , Xν′) = 0.2, ν 6= ν ′. Treatment A ∈ {−1, 1} was randomly as-
signed with equal probability to each subject with P (A = 1 |X) = P (A = −1 |X) =
0.5. Subjects were measured at m = 5 follow-up times in addition to a baseline visit,
with the scaled times as tj = j/m and the standardized time t̃j = tj/tm, j = 1, . . . ,m.
A set of cubic spline plus basis function s(tj) was specified with three knots at




j , (tj −
k1)
3
+, (tj−k2)3+, (tj−k3)3+)ᵀ at visit j to represent the time trajectory. The underlying
true decision function f was specified as f(X) = 1+X1−log(X2+1)+2X33−exp(X4).




where β3 = β4 = (3, 0.5, 0.5,−3.5,−2,−2,−0.1)ᵀ, random intercepts γi
i.i.d∼ N(0, 0.5)
and random errors εi
i.i.d∼ MVN(0,Σ) with Σ(ρ) being an AR(1) correlation ma-
trix and correlation coefficient ρ = 0.5. The missing outcome indicator Rij for
each outcome Bij was generated independently according to a Bernoulli distribu-
tion with probability (a) P (Ri1 = 1) = 0.01 for the first measurement Bi1 and (b)
logit P (Rij = 1) = 1 + 2t̃j − 0.005Bij−1 for j = 2, . . . ,M . The outcome Bij−1 at the
adjacent visit j − 1 was included to represent the not missing at random (NMAR)
mechanism since Bij−1 may not be observed. Based on the missing patterns, subjects
can be stratified into subgroups Sj, j = 1, . . . ,m according to the available last obser-
vations. Although subjects were completely randomized to one of the two treatment
groups, balancing may be broken due to missing data. Therefore, propensity scores
of treatment assignment for each subject was estimated by a logistic regression model
based on all the majors effects of the covariatesX. The total sample size for the train-
ing data S = S1 ∪ · · · ∪ Sm was set as n = 1000. In addition, an independent testing
dataset of sample size 5000 with the true labels determined by f(X) > 0 or not was
generated as an external validation data. An ITR was derived using the LS-learning
method under linear kernel. Scaled tuning was performed via an exponential function
ψ(t̃j | θ) = θ1eθ2 t̃j with θ2 = log(1/θ1) to characterize the relevant time course of the
outcomes to the endpoint benefit measured at visit m. We set two tuning parameter
pools C ∈ {1/128, 1/64, . . . , 1/2, 1} and θ1 ∈ {0.1, 0.2, . . . , 0.9, 1.0} respectively, for
tuning parameter selection. The GAM regression with B-spline basis functions (20
basis functions for each variable) was employed to estimate mean prediction function




We compared five methods for their prediction accuracy on both training and
validation datasets. They are, (M1) OWL on the whole training data S with no
missing data. The endpoint Bm is fully observed and used for ITR derivation using
the standard OWL. This serves as the gold standard, termed as the super oracle
method, for the purpose of comparison. Note that the endpoint benefit Bm is often
not available in practice due to missing data. (M2) LS-learning with scaled tuning
on the whole training data S with missing data. It incorporates auxiliary benefits
Bj, j = 1, . . . ,m − 1 prior to the endpoint Bm using subject stratification. We de-
rive ITR using LS-learning that takes into consideration the relevance of time course
outcomes. (M3) OWL on the whole training data S with missing imputation under
LOCF. It differs from M2 by ignoring the incorporation of time course outcomes.
(M4) OWL on the whole training data with missing data, where missing informa-
tion is imputed by multiple imputation via the R package MICE (van Buuren and
Groothuis-Oudshoorn, 2011). The imputed endpoint Bm is used for ITR derivation
via the standard OWL. Five imputed datasets were created using all the available
data of X, A and observed benefits from which the average statistics of OWL perfor-
mances are calculated. (M5) OWL on the training data of available endpoint benefits
from those who are the completers of the clinical trial. All the methods based on the
standard OWL, including M1, M3, M4, and M5, use 5-fold cross-validation for tuning
parameter selection as proposed in Zhao et al. (2012). Table 4.2 lists the average pre-
diction accuracy with the standard deviations on the training and validation datasets.
It is shown that as expected, the super oracle M1 always gives the highest prediction
accuracy since it uses the complete information for ITR derivation. However, M1 is
not available in practice in the presence of missing data. The LS-learning method
M2, which is developed with missing data, gives a slightly lower prediction accuracy
compared to M1. Clearly, the prediction accuracy given by M3-M5 are much lower
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Table 4.2: Average prediction accuracy (mean (sd)) on both training and validation
datasets among the five methods to derive ITR.
Method Prediction Accuracy (Training) Prediction Accuracy (Validating)
M1 0.841 (0.034) 0.841 (0.033)
M2 0.815 (0.044) 0.813 (0.043)
M3 0.799 (0.048) 0.798 (0.047)
M4 0.743 (0.071) 0.741 (0.070)
M5 0.558 (0.096) 0.557 (0.097)
Table 4.3: Estimated value functions evaluated as B1 to B5 on the training data S
for five methods of ITR derivation.
method V̂ (B1) V̂ (B2) V̂ (B3) V̂ (B4) V̂ (B5)
M1 10.07 (0.57) 10.07 (0.60) 9.70 (0.60) 8.78 (0.64) 6.90 (0.62)
M2 10.02 (0.58) 10.02 (0.60) 9.65 (0.60) 8.73 (0.66) 6.85 (0.63)
M3 9.98 (0.58) 9.99 (0.60) 9.60 (0.60) 8.69 (0.65) 6.82 (0.64)
M4 9.82 (0.60) 9.83 (0.63) 9.43 (0.62) 8.56 (0.66) 6.63 (0.66)
M5 9.24 (0.60) 9.22 (0.68) 8.87 (0.66) 7.95 (0.68) 6.12 (0.68)
than that of M2.
We calculated the estimated value functions evaluated at the five outcomes V̂ (Bj)
on the whole training data S. These estimates are listed in Table 4.3. It is shown that
the super oracle M1 always gives the highest estimated value function as expected.
The LS-learning with scaled tuning method M2 gives higher estimated value functions
than the other three OWL methods M3, M4, and M5. In LS-learning, the mean (sd)
of the selected tuning parameter θ1 in the exponential function equals 0.800 (0.270),
resulting in the mean tuning parameters λ1 = 0.837, λ2 = 0.875, λ3 = 0.915, λ4 =
0.956 for B1 to B4, respectively. It demonstrates a decreasing trend for the relevance
of outcomes from the endpoint to the first visit time. But the relevance remains
strong since λ1 = 0.875 is a relatively large weight of overlap for B1 with B5.
To compare computation time between LS-learning with greedy tuning and LS-
learning with scaled tuning is of interest. Scaled tuning is proposed to save computa-
tion and costs for LS-learning by reducing the number of tuning parameters. In this
simulation, should the greedy tuning be adopted, we need to tune a total of four λ
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values (λj, j = 1, . . . , 4), which is reduced to one by scaled tuning. The latter took, on
average, 6,492.96 seconds, while the greedy tuning is estimated as 9,506,343 seconds
(i.e. 110.03 days) under four sequence of grids λj ∈ {0, 0.1, . . . , 1.0}, j = 1, . . . , 4.
Obviously, the computation efficiency of the scaled tuning method makes LS-learning
practically feasible.
4.5 Derivation of ITR for Longitudinal Calcium Trial
We apply the LS-learning approach with the scaled-tuning scheme to analyze the
longitudinal calcium supplementation trial. The central objective of our analysis is
to derive an ITR that can guide pregnant women to take calcium supplementation
in order to minimize persistent lead exposure for their children at age of 3 years old.
The PBC values are measured repeatedly at a total of seven different follow-up times
at month 3, 6, 12, 18, 24, 30, and 36, denoted as B1, . . . , B7 respectively, where B7
is designed as the primary endpoint of interest. It is reasonable to assume that the
quality of these longitudinal outcomes increases when time of a PBC measurement
approaches to month 36. A total of 376 mother-child pairs with no missing data at
the baseline visit are used for our ITR derivation, with 190 mothers taking calcium
supplementation and 186 mothers taking placebo. Stratification of mother-child pairs
into strata S1, . . . ,S7 based on the primary endpoint for the completers and surrogate
endpoints for the noncompleters are illustrated in Figure 4.1(b). Section 4.2 presents
more details of the study design and data of the trial.
Since children on the two treatment arms are not fully balanced due to missing
data, propensity scores are estimated by a logistic regression model with all the
major effects of the predictors. Similar to the analysis performed in Section 3.5,
after weighting the PBC values by the estimated propensity scores, we evaluate the
balance of the propensity scores in Figure 4.4(a) and more importantly the balance
of individual predictor’s distribution using the absolute standardized mean difference
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Figure 4.4: (a) Distributional balance of the propensity scores before and after weight-
ing. (b) Balance of individual predictor before and after weighting ad-
justed by ASMD under threshold 0.1, indicated by the dashed lines.
(ASMD) in Figure 4.4(b). Figure 4.4(b) shows clearly that the balance of predictor’s
distribution is satisfactorily reached, as for all individual predictors their ASMDs
(denoted by solid dots) have met within a threshold of 0.1 (Austin, 2009).
We now derive ITR for the daily intake of calcium supplementation. We perform:
(i) a standard OWL on the stratum of completers, S7 with PBC B7 (or PBC36),
and the resulting decision rule is denoted as f̂1; (ii) a standard OWL on the whole
training data S with missing data imputed by the method of multiple imputation
via the R package MICE (van Buuren and Groothuis-Oudshoorn, 2011), resulting in
the estimated decision rule f̂2; (iii) a standard OWL on the whole training data S
with missing PBC36 replaced by the last observed PBC under the so-called strategy
of last observation carried forward (LOCF) (Molnar et al., 2008). In effect, LOCF
implies that the last observed PBC is used as endpoint outcome for ITR derivation.
Clearly, this approach ignores the differential relevance of longitudinal outcomes in
the reference to the primary endpoint PBC36 measured at month 36. From the
tuning parameter point of view, this is equivalent to setting naively λj = 1, j =
1, . . . , 6. The estimated decision rule is denoted as f̂3; (iv) our LS-learning with
the scaled tuning scheme on the whole training data S, which takes into account
differences among longitudinal outcomes Bj, j = 1, . . . , 6 in terms of their relevance
to PBC36, and this leads to an estimated decision rule f̂4. In LS-learning, we use
70
Table 4.4: Estimated intercepts and coefficients of the predictors in the estimated
ITRs.
f̂1 f̂2 f̂3 f̂4
intercept 0.40 0.08 0.08 0.18
age 0.45 0.37 0.35 0.51
weight 0.10 0.02 0.03 0.03
school 0.01 -0.04 -0.02 -0.03
married 0.20 0.17 0.14 0.19
parity -0.55 0.01 0.12 -0.16
HgB 0.12 0.13 0.13 0.10
Ca -0.42 -0.28 -0.28 -0.46
fiber 0.34 0.23 0.24 0.26
Fe -0.11 0.05 0.03 0.08
Zn 0.26 0.29 0.32 0.53
VC 0.06 -0.15 -0.19 -0.04
PBM -0.40 -0.43 -0.43 -0.47
the linear kernel in the optimization function (4.1) to train ITR with the utility of
the exponential scaling function for tuning (the middle panel of Figure 4.3). We set
C ∈ {1/128, 1/64, . . . , 1/2, 1} and θ1 ∈ {0.1, 0.2, . . . , 0.9, 1.0} for the tuning parameter
selection. The loading coefficients of the predictors in the above four estimated ITRs
are listed in Table 4.4.
According to the exponential scaling procedure, we obtain a tuning parameter
θ1 = 0.1, which generates λ1 = 0.121, λ2 = 0.147, λ3 = 0.215, λ4 = 0.316, λ5 = 0.464
and λ6 = 0.681 for f̂4. In this LS-learning, we use two tuning parameters, C and
θ1, each having 8 and 10 different values, respectively, resulting in a total of 80
different pairs of C and θ1. In contrast, if we use a greedy tuning strategy under
λj ∈ {0, 0.1, . . . , 1.0}, j = 1, . . . , 6, we would have to deal with a total of 8 × 116 =
14, 172, 488 pairs in tuning. As a result, our scaling procedure has saved 177,156 folds
of computational runs.
Applying each of the four estimated decision rules above, we would allocate a preg-
nant woman to take calcium supplement if f̂ > 0; otherwise, not to take the supple-
ment. Among 376 mothers, f̂1, f̂2, f̂3 and f̂4 would assign 233 (62.0%), 243 (64.6%),
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Table 4.5: Treatment assignment comparison between complete randomization and
f̂4 estimated by LS-learning.
f̂4
placebo calcium total
randomization placebo 87 90 177
calcium 59 131 190
total 146 221 367
254 (67.6%) and 230 (61.2%) women to take calcium supplement, respectively, all
higher than 50% given in the randomized assignment. In particular, comparing be-
tween complete randomization and the LS-learning f̂4, as shown in Table 4.5, we
see significant differences in the reallocation of calcium supplement. We conduct the
McNemar test for the hypothesis of homogeneous allocation distribution, and obtain
p-value of 0.0015, indicating that there exists a significant discrepancy between the
two allocation rules, and in other words, these different treatment assignments do not
occur by accident.
In addition, we calculate the SSE values to assess the quality of prediction by
f̂1, f̂2, f̂3 and f̂4. They are 1117.2, 1113.5, 1114.1 and 923.3, respectively. This sug-
gests that the LS-learning f̂4 achieves the smallest SSE or the best prediction of the
benefit values. To compare the performances of f̂1, f̂2, f̂3 and f̂4 in minimizing con-
tinuous lead exposure over different time points, we calculate the estimated value
functions V̂ (Bj) of Bj, j = 1, . . . , 7 using E∗n[I(A = D(X))B/P (A | X)]/E∗n[I(A =
D(X))/P (A |X)] (Murphy et al., 2001). The estimated value functions for longitu-
dinal outcomes at individual visit times as well as their averages are summarized in
Table 4.6. Clearly, the LS-learning f̂4 gives the highest average estimated value func-
tion, producing the lowest continuous lead exposure in comparison to the other three
decision rules f̂1, f̂2 or f̂3. This indicates that the utility of the longitudinal auxiliary
data via surrogate outcomes Bj, j = 1, . . . , 6 has arguably improved the estimated
ITR to maximally benefit children in their growth and development. This improve-
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Table 4.6: Estimated value functions at each visit and the average based on the esti-
mated ITR f̂1, f̂2, f̂3 and f̂4 derived in the calcium supplementation trial.
ITR V̂ (B1) V̂ (B2) V̂ (B3) V̂ (B4) V̂ (B5) V̂ (B6) V̂ (B7) Average
f̂1 9.1 10.6 9.4 6.3 8.1 8.1 8.3 8.56
f̂2 9.6 10.2 9.4 6.3 8.5 8.1 8.3 8.63
f̂3 9.6 9.6 9.4 6.8 8.4 8.1 8.3 8.60
f̂4 9.6 10.6 9.4 6.3 8.5 8.1 8.3 8.69
ment is rooted in a successful use on the ordering of time-course relevance among
longitudinal outcomes in the multi-view extension of OWL with multiple training
datasets.
We also compare individual predictor’s distributions between the two resulting
treatment groups by the LS-learning decision function f̂4; see Table 4.7, through
which we identify those predictors that are significantly different between the two
groups. We found that mothers assigned by f̂4 to take calcium supplementation have
a significantly older age, higher weight, longer years in school, higher proportion of
marriage, higher dietary intake of fiber, Fe, Zn and vitamin C, and lower maternal
baseline blood lead concentration (PBM) (see Table 4.7). It is interesting to note that
mothers assigned to the calcium supplement group by f̂4 do not have a significant
difference in their dietary calcium intake from food compared to those assigned to
the placebo group (11.4 (5.2) versus 10.4 (5.2)). This suggests that maternal dietary
intake of calcium on baseline may not influence children’s persistent lead exposure at
age 3. This finding is of clinical value, as some pregnant women refuse to take calcium
supplementation under their misbelief of being able to obtain adequate amount of
calcium from food. In addition, no significant differences were identified for the total
number of pregnancies and the maternal baseline HgB concentration between the two
resulting allocation groups by f̂4.
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Table 4.7: Summary statistics of the predictors based on treatment allocation accord-
ing to f̂4. Mean (sd) and percentage values are shown, where p-values are
obtained from Wilcoxon rank-sum test and chi-aquare test for numeric and
categorical variables, respectively.
Predictor Calcium Placebo p-value
age 28.3 (5.2) 23.4 (4.7) 4.36× 10−17
weight 62.9 (10.9) 60.1 (9.7) 9.56× 10−3
school 11.2 (3.1) 10.1 (2.4) 2.14× 10−4
married 0.735 0.610 1.49× 10−2
parity 2.1 (1.0) 2.0 (1.0) 3.30× 10−1
HgB 13.3 (0.8) 13.0 (1.2) 8.84× 10−2
Ca 11.4 (5.2) 10.4 (5.2) 8.15× 10−2
fiber 26.4 (9.2) 19.2 (8.3) 1.33× 10−14
Fe 14.9 (5.6) 10.8 (5.0) 1.76× 10−12
Zn 10.5 (3.4) 7.9 (3.2) 7.44× 10−13
VC 193.6 (84.7) 146.9 (81.6) 1.43× 10−8
PBM 4.0 (2.3) 6.4 (3.9) 2.64× 10−11
4.6 Concluding Remarks
In this chapter, we utilize a newly proposed LS-learning method to establish ITRs
in that we integrate longitudinal data sources with time-varying relevance to the
primary clinical endpoint. Our method provides a useful extension of the existing one-
dimensional cross-sectional OWL method by allowing temporally correlated outcomes
in the search of optimal ITR. We introduce additional tuning parameters to synergize
different training data sources with varying degrees of relevance to the primary data
source. The proposed method is particularly appealing in real clinical studies where
repeated measurements are often collected with missing data that would lead to data
attrition and loss of statistical power if no appropriate strategy is invoked to handle
this issue. Meanwhile, we propose and test a scaled tuning procedure in LS-learning
to greatly reduce computational burden in the tuning parameter selection.
We apply LS-learning to derive an ITR for pregnant women in their daily intake of
calcium supplementation to lower persistent lead exposure by their children at age 3
years old. The major difficulty in analyzing this clinical trial data lies in the fact that
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there are a substantial amount of missing values of PBC over the three-year period
of the study. The LS-learning stratifies subjects into subgroups of outcomes based on
respective missing patterns in a similar way considered in the pattern mixture model
proposed by Little (2008). It is shown that the new ITR derived by LS-learning
would lead to a larger reduction of persistent lead exposure to children in comparison
to other ITRs given by standard OWL, if the new one were implemented for the
whole target population of pregnant women. In addition to the real data application,
a comprehensive simulation experiment in Section 4.4 shows that LS-learning outper-
forms the standard OWL in ITR estimation according to the prediction accuracy as
well as the estimated value functions. Meanwhile, we have identified several baseline
predictors that may play important roles in allocating calcium supplementation, such
as dietary intake of fiber, Fe, Zn and vitamin C.
One limitation of our data analysis is the use of linear kernel for ITR derivation
because of its ease in illustrating the estimated decision rules. Nonlinear-kernels can
also be applied to derive more flexible decision rules, which may be further explored
as a future extension. Another challenge pertains to the imbalance of treatment as-
signment in the cleaned data caused mostly by missing baseline predictors. We have
adopted the means of propensity score via inverse probability weighting (IPW) to
adjust the treatment allocation bias. Other methods, like augmented inverse prob-
ability weighting (AIPW) (Glynn and Quinn, 2010) and overlap weighting (Thomas
et al., 2020), are worth a further exploration to overcome the treatment assignment
bias in the ITR analysis of calcium supplementation clinical trial.
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CHAPTER V
Summary and Future Work
Focusing on individualized treatment rules (ITRs) in the filed of personalized
healthcare, this dissertation has delivered improvements and extensions of ITR method-
ologies, with specific applications in precision medicine and precision nutrition. Var-
ious methods have been developed to derive ITR that allows to tailor treatments for
patients with heterogeneous responses, and consequently maximizes their therapeu-
tic effects. However, many methodological challenges still remain to be addressed for
better ITR. Some of the ITR improvements considered in this dissertation include
(i) to improve and validate existing ITRs through the use of potential new candidate
biomarkers, (ii) to establish ITRs via a multi-view approach with multiple benefit
outcomes, and (iii) to derive ITRs in the presence of missing information in training
data. These tasks are not trivial analytically, while are of critical importance in real
clinical practice.
The objective of validating existing ITRs using candidate biomarkers has led to
the development of the net benefit index (NBI) method in Chapter II. We proposed
a new statistical framework, NBI, to quantify added values of candidate biomarkers
and select those significantly important ones to be included in an existing ITR. This
selection is done by a rigorous NBI-based test. Another difficult task in ITR derivation
is to establish ITR in the presence of multiple benefit outcomes, which are typically
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of various quality and clinical relevance with missing data. These complications are
encountered in the ITR derivation for precision nutrition, where patients have been
observed for multiple benefit responses in a longitudinal clinical trial. Driven by these
complicating factors, we developed two methods, termed synergistic self-learning (SS-
learning) and longitudinal self-learning (LS-learning), respectively, in Chapter III and
Chapter IV. SS-learning and LS-learning are two self-iterative procedures that allow
the integration of multiple benefit outcomes into ITR derivation, which extends the
existing one-dimensional method for of ITR derivation.
The three methods proposed in this dissertation can be further improved as have
been discussed at the end of the respective chapters. For future research, the effort
should be made on borrowing the strengths of the proposed methods and pairing them
with new methodologies in the fast growing literature in machine learning for further
generalization of ITR methodology. Here, we conclude this dissertation by pointing
out several potential future research directions on ITR derivation for personalized
healthcare.
One promising direction of future research is to extend the derivation of ITR
from trials with categorized treatment levels to clinical studies of continuous dosage
amounts. One limitation of the proposed NBI method, SS-learning, and LS-learning is
that they can only deal with the allocation of binary treatment arms, for example, new
treatment and standard treatment or placebo. Such an ITR estimation problem with
categorical treatment levels may actually be formulated as a classification problem,
which is solved by certain machine learning methods like support vector machine
(SVM). One of such example is outcome weighted learning (OWL) reported by Zhao
et al. (2012). However, in real clinical practice, medications and therapies may be
allocated to patients with some continuous dosage amounts. Therefore, it seems of
great interest to estimate the optimal individualized dosage of medicine in real clinical
studies. Methods have already been developed for dose finding in ITR derivation,
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like Chen et al. (2016), in which the authors propose an OWL-based method with
a nonconvex loss function that can be solved by an algorithm based on a difference
of convex functions. Kernel-based and Bayesian methodologies are also emerging in
optimal individualized dose finding; see for examples Zhu et al. (2020) and Liu and
Johnson (2016). Future research is needed to develop robust and clinical relevant
methods of continuous dose finding for ITR derivation.
In the advent of electronic health records (EHR) data, another promising fu-
ture research direction is to establish ITR using big data from observational studies,
such as those EHR databases. Different from randomized trials, subjects’ records
in EHR databases do not receive random treatment assignments. This kind of non-
experimental study suffers from selection bias and unmeasured confounding, which
challenge the establishment of inference for causality. In this case, some propensity
score methods are inevitable to adjust high-dimensional confounding and selection
biases. One recent publication (Wu et al., 2020) proposes a machine learning ap-
proach based on matching (M-learning) to deal with the problem of ITR derivation
using EHR data. This newly proposed M-learning method employs matching instead
of inverse probability weighting (IPW), which is the approach that is commonly used
in many existing methods like OWL for ITR estimation, to better evaluate individ-
ual responses to different treatments and alleviate confounding associated with EHR
data. The proposed matching-based value function can serve as a unified framework
that can accommodate the use of other types of outcomes, such as continuous, ordi-
nal, and discrete outcomes, in ITR derivation. This also provides another promising
direction to extend the current ITR derivation methods to deal with various benefit
outcomes types. Along this line of future research, other propensity score matching
methods or weighting schemes can also be examined in the setting of ITR estimation
under the M-learning framework using EHR data.
Last but not least, we plan to develop online ITR estimation methods using
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streaming data, with the objective that we want to update ITR by some online
estimation methods when training data become available sequentially over time. An
online ITR avoids re-estimating ITR using the entire training dataset that grows se-
quentially. With the quick growth of EHR data, online ITR estimation methods that
can deal with growing large EHR databases are appealing. It allows us to establish
robust and reproducible decision functions in a reasonable amount of time. Streaming
classification is a topic that has been studied in machine learning (Mu et al., 2017;
Abdulsalam et al., 2010; Street and Kim, 2001; Nair et al., 2018). Such online clas-
sification methods are able to handle intermittent arrival of labeled records, and to
adjust parameters in respond to changing class boundaries in data streams. We plan






Outcome Weighted Learning (OWL)
Denote the space of the observed data as (X, A,B). The distribution of (X, A,B)
is denoted as P and the expectation of B with respect to P is denoted as E. Given
a specific decision rule D, the distribution of (X, A,B) where A = D(X) is denoted
as PD, and the expectation of B with respect to PD is denoted as ED. The expected
clinical benefit under the given D can be calculated as the value function














The optimal decision rule will be D∗ such that









which is equivalent to









The term I(A 6=D(X))
P (Ai|Xi) B is actually a weighted classification error. Therefore, OWL
is a weighted classification problem. With a set of i.i.d observations (Xi, Ai, Bi), we
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can approximate the optimization problem in (A.3) by the empirical value








I{Ai 6= D(Xi)}. (A.4)
Since D(X) can always be represented as sign(f(X)) for some decision function
f , where
D(X) =
 1, f(X) > 0,−1, f(X) < 0,
the optimization problem in (A.4) is equivalent to:








I{Ai 6= sign(f(Xi))} (A.5)
We can first obtain the optimal decision function f ∗ based on the optimization of
(A.5), and then set D∗(X) = sign(f ∗(X)) to get the optimal decision rule D∗.
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APPENDIX B
Support Vector Machine (SVM) solution to OWL
The optimization problem (A.5) is a weighted summation of 0-1 loss, which is
neither convex nor continuous. It makes the problem difficult to be solved directly.
Therefore, OWL uses a convex surrogate hinge loss x+ = max(0, x), which is com-
monly used in SVM, to replace the 0-1 loss. In order to further penalize the complex-
ity of the decision function f to avoid overfitting, OWL adds a l2 penalty into the







(1− Aif(Xi))+ + λn||f ||2, (B.1)
where λn is the regulization parameter. This optimization problem can be solved
using the technique of SVM.
If we assume that the decision rule f is a linear function f(X) = β0 + Xβ,
the optimization problem of OWL can be solved as follows by introducing the slack
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i β + β0) ≥ 1− ξi
ξi ≥ 0, i = 1, ..., n.
(B.2)
Let κ = 1
2nλn












i β + β0) ≥ 1− ξi
ξi ≥ 0, i = 1, ..., n.
(B.3)




















where αi is the Lagrange Multiplier. If we assume a nonlinear decision rule f , the






















Multiple-variable-based ITR Derivation when
Xe = Null for Chapter II
This simulation concerns a setting where Xe = Null. We have multiple signal
and noise candidate biomarkers, Xj ∼ U(0, 1), j = 1, . . . , 10, in which only X1 and
X2 are signal biomarkers involved in the optimal ITR. The correlation structure
of the variables is that Corr(X1, X3) = Corr(X2, X4) = 0.5, and Corr(Xs, Xt) =
0.2, s, t ∈ {5, . . . , 110}, s 6= t. B is generated from a normal distribution with mean
µ = 0.5 +X1 + 2.0Af(X), where f(X) is given as follows:
7) (Linear) f(X) = 0.5(1 + 2X1 − 4X2);
8) (Binary) f(X) = 6{I(X1 > 0.29 ∩X2 < 0.71)− 0.5};
9) (Nonlinear) f(X) = (X1 − 0.1)+ − (X2 − 0.22)+.
Summary statistics of variable selection based on the proposed NBI test method, SAS
and riskRFE are included in Table C.1.
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Table C.1: Size, TDR, MCC, and CCR for variable selection based on NBI test, SAS,
and riskRFE in the multiple-variable-based decision rule evaluation when
Xe = Null.
NBI
scenario n size (sd) TDR (sd) MCC (sd) CCR (sd)
linear 800 1.799 (0.761) 0.915 (0.192) 0.797 (0.221) 0.871 (0.068)
1000 1.895 (0.777) 0.918 (0.181) 0.826 (0.207) 0.880 (0.067)
1200 1.934 (0.707) 0.917 (0.184) 0.844 (0.211) 0.881 (0.069)
binary 800 2.115 (0.617) 0.935 (0.151) 0.921 (0.149) 0.905 (0.072)
1000 2.145 (0.590) 0.937 (0.150) 0.933 (0.142) 0.909 (0.070)
1200 2.136 (0.467) 0.948 (0.134) 0.953 (0.120) 0.914 (0.061)
nonlinear 800 1.957 (0.840) 0.898 (0.216) 0.814 (0.243) 0.840 (0.087)
1000 2.045 (0.914) 0.893 (0.209) 0.828 (0.232) 0.847 (0.080)
1200 1.977 (0.771) 0.912 (0.195) 0.842 (0.224) 0.855 (0.081)
SAS
scenario n size(sd) TDR(sd) MCC(sd) CCR(sd)
linear 800 2.096 (0.295) 0.968 (0.098) 0.977 (0.070) 0.988 (0.007)
1000 2.034 (0.192) 0.989 (0.061) 0.992 (0.044) 0.989 (0.006)
1200 2.022 (0.147) 0.993 (0.049) 0.995 (0.035) 0.991 (0.005)
binary 800 2.502 (0.712) 0.852 (0.190) 0.891 (0.143) 0.825 (0.011)
1000 2.316 (0.584) 0.904 (0.166) 0.930 (0.123) 0.828 (0.011)
1200 2.208 (0.457) 0.934 (0.139) 0.953 (0.101) 0.826 (0.012)
nonlinear 800 3.228 (1.065) 0.688 (0.219) 0.760 (0.179) 0.963 (0.015)
1000 2.840 (0.903) 0.769 (0.213) 0.827 (0.166) 0.964 (0.015)
1200 2.672 (0.826) 0.810 (0.207) 0.859 (0.158) 0.967 (0.012)
riskRFE
scenario n size(sd) TDR(sd) MCC(sd) CCR(sd)
linear 800 2.686 (0.955) 0.756 (0.229) 0.774 (0.217) 0.925 (0.042)
1000 2.443 (0.829) 0.813 (0.228) 0.815 (0.227) 0.928 (0.045)
1200 2.219 (0.676) 0.870 (0.196) 0.854 (0.198) 0.932 (0.035)
binary 800 3.312 (1.037) 0.646 (0.209) 0.714 (0.192) 0.859 (0.108)
1000 2.985 (0.968) 0.710 (0.215) 0.763 (0.186) 0.883 (0.093)
1200 2.638 (0.904) 0.783 (0.216) 0.810 (0.192) 0.885 (0.085)
nonlinear 800 2.969 (1.087) 0.672 (0.244) 0.691 (0.249) 0.842 (0.069)
1000 2.645 (0.958) 0.741 (0.244) 0.746 (0.245) 0.845 (0.071)
1200 2.401 (0.842) 0.789 (0.236) 0.773 (0.241) 0.853 (0.076)
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APPENDIX D
Additional Simulation Experiments for Chapter II
Table D.1 lists the summary statistics of variable selection based on the proposed
NBI method, SAS and riskRFE in the multiple-variable-based decision rule evalu-
ation when Xe 6= Null and n = 200. Table D.2 lists the summary statistics of
variable selection based on the proposed NBI test method, SAS and riskRFE in the
multiple-variable-based decision rule evaluation when Xe = Null and NBI is calcu-
lated under the Gaussian kernel. In this simulation setting, the true decision rule
f is set as f(X) = exp(X21 ) − exp(X22 ). Table D.3 is the comparison of prediction
accuracy for the ITRs derived under NBI test and the standard OWL in the multiple-
variable-based decision rule evaluation whenXe 6= Null. Table D.4 lists the summary
statistics of variable selection based on l1-OWL in the multiple-variable-based decision
rule evaluation when Xe = Null.
We also report the simulation results (see Table D.5-D.7) for an additional single-
variable-based nonlinear decision rule (f(X) = 1 + X1 + X
3
2 − exp(X3)) and an
additional multiple-variable-based nonlinear decision rule (f(X) = 1.5{1 + X1 −
log(X2 + 1) + 2X
3
3 − exp(X4)}). It is seen that NBI still gives good variable selection
results in the single-variable-based decision rule evaluation, while in the multiple-
variable-based decision rule evaluation, SAS outperforms NBI. It is interesting to note
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Table D.1: Size, TDR, MCC, and CCR for variable selection based on NBI test, SAS
and riskRFE in the multiple-variable-based decision rule evaluation when
n = 200.
NBI
scenario size (sd) TDR (sd) MCC (sd) CCR (sd)
linear 1.321 (1.327) 0.549 (0.443) 0.414 (0.364) 0.707 (0.106)
binary 1.235 (1.186) 0.538 (0.447) 0.403 (0.371) 0.654 (0.081)
nonlinear 1.637 (1.685) 0.580 (0.431) 0.430 (0.372) 0.686 (0.108)
SAS
scenario size (sd) TDR (sd) MCC (sd) CCR (sd)
linear 6.819 (2.154) 0.323 (0.140) 0.316 (0.239) 0.918 (0.039)
binary 7.626 (1.984) 0.262 (0.104) 0.189 (0.236) 0.723 (0.023)
nonlinear 7.246 (2.046) 0.295 (0.120) 0.271 (0.226) 0.889 (0.043)
riskRFE
scenario size (sd) TDR (sd) MCC (sd) CCR (sd)
linear 5.325 (1.503) 0.330 (0.156) 0.296 (0.301) 0.747 (0.081)
binary 6.223 (1.418) 0.321 (0.102) 0.342 (0.204) 0.645 (0.100)
nonlinear 5.304 (1.570) 0.323 (0.156) 0.286 (0.291) 0.727 (0.081)
that in scenario n = 1200, SAS gives the perfect results with size=2.000, TDR=1.000
and MCC=1.000, with ZERO standard deviation. This does not seem to be an
appropriate setting to reflect a real-world scenario. Such perfection may be resulted
from too strong signal-to-noise ratio in the previously chosen nonlinear decision rule.
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Table D.2: Size, TDR, MCC, and CCR for variable selection based on NBI test, SAS
and riskRFE in the multiple-variable-based decision rule evaluation when
SVM is performed under Gaussian kernel.
NBI
scenario n size(sd) TDR(sd) MCC(sd) CCR(sd)
nonlinear 800 2.125 (0.413) 0.958 (0.116) 0.966 (0.090) 0.878 (0.062)
1000 2.175 (0.506) 0.949 (0.132) 0.962 (0.099) 0.884 (0.061)
1200 2.150 (0.410) 0.951 (0.124) 0.963 (0.092) 0.890 (0.052)
SAS
scenario n size(sd) TDR(sd) MCC(sd) CCR(sd)
nonlinear 800 2.327 (0.604) 0.902 (0.168) 0.928 (0.125) 0.990 (0.007)
1000 2.183 (0.426) 0.941 (0.131) 0.958 (0.095) 0.991 (0.006)
1200 2.105 (0.341) 0.967 (0.104) 0.976 (0.075) 0.992 (0.005)
riskRFE
scenario n size(sd) TDR(sd) MCC(sd) CCR(sd)
nonlinear 800 2.320 (0.467) 0.783 (0.279) 0.776 (0.338) 0.811 (0.109)
1000 2.200 (0.400) 0.798 (0.293) 0.777 (0.360) 0.819 (0.106)
1200 2.168 (0.374) 0.816 (0.277) 0.795 (0.340) 0.832 (0.101)
Table D.3: Prediction accuracy for ITRs derived by NBI and the standard OWL in
the multiple-variable-based decision rule evaluation.
scenario n CCR (sd) NBI CCR (sd) OWL
linear 800 0.835 (0.081) 0.837 (0.037)
1000 0.852 (0.076) 0.850 (0.039)
1200 0.870 (0.070) 0.862 (0.035)
binary 800 0.765 (0.098) 0.649 (0.121)
1000 0.786 (0.095) 0.667 (0.125)
1200 0.805 (0.090) 0.666 (0.125)
nonlinear 800 0.818 (0.081) 0.821 (0.042)
1000 0.832 (0.075) 0.830 (0.041)
1200 0.847 (0.073) 0.841 (0.037)
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Table D.4: Size, TDR, MCC and CCR in the multiple-variable-based decision rule
evaluation based on l1-OWL when Xe = Null.
scenario n size (sd) TDR (sd) MCC (sd) CCR (sd)
linear 800 6.031 (3.358) 0.212 (0.197) 0.022 (0.288) 0.771 (0.161)
1000 6.337 (3.203) 0.190 (0.159) -0.013 (0.289) 0.785 (0.162)
1200 6.744 (3.040) 0.190 (0.133) -0.005 (0.271) 0.802 (0.156)
binary 800 5.950 (3.416) 0.187 (0.167) -0.002 (0.276) 0.653 (0.144)
1000 6.226 (3.163) 0.189 (0.159) -0.012 (0.289) 0.665 (0.147)
1200 6.757 (3.143) 0.199 (0.139) 0.005 (0.274) 0.679 (0.147)
nonlinear 800 5.887 (3.353) 0.196 (0.179) 0.003 (0.280) 0.731 (0.115)
1000 6.427 (3.211) 0.199 (0.165) -0.010 (0.290) 0.758 (0.110)
1200 6.543 (2.968) 0.197 (0.144) -0.004 (0.297) 0.769 (0.107)
Table D.5: Discovery rates for X3 and X4 in the single-variable-based decision rule
evaluation for the additional nonlinear setting. (Discovery rate for X4
equals 1-specificity.)
ρ = 0.0 ρ = 0.2 ρ = 0.5 ρ = 0.8
scenario n X3 X4 X3 X4 X3 X4 X3 X4
nonlinear 800 0.977 0.055 0.977 0.054 0.965 0.058 0.855 0.051
1000 0.981 0.057 0.985 0.057 0.969 0.054 0.872 0.045
1200 0.991 0.052 0.989 0.037 0.98 0.045 0.918 0.048
Table D.6: NBI values for X3 and X4 in the single-variable-based decision rule eval-
uation for the additional nonlinear decision rule.
ρ = 0.0 ρ = 0.2
scenario n X3 mean (sd) X4 mean (sd) X3 mean (sd) X4 mean (sd)
nonlinear 800 1.443 (0.609) -0.151 (0.633) 1.424 (0.604) -0.153 (0.662)
1000 1.405 (0.584) -0.124 (0.613) 1.404 (0.572) -0.112 (0.613)
1200 1.421 (0.517) -0.122 (0.595) 1.379 (0.520) -0.168 (0.562)
ρ = 0.5 ρ = 0.8
scenario n X3 mean (sd) X4 mean (sd) X3 mean (sd) X4 mean (sd)
nonlinear 800 1.266 (0.642) -0.158 (0.646) 0.863 (0.646) -0.143 (0.642)
1000 1.233 (0.646) -0.110 (0.600) 0.819 (0.649) -0.139 (0.623)
1200 1.221 (0.560) -0.159 (0.595) 0.867 (0.571) -0.123 (0.611)
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Table D.7: Size, TDR, MCC, and CCR for variable selection based on NBI test, SAS
and riskRFE in the multiple-variable-based decision rule evaluation for
the additional nonlinear decision rule.
NBI
scenario n size (sd) TDR (sd) MCC (sd) CCR (sd)
nonlinear 800 2.064 (0.588) 0.936 (0.161) 0.912 (0.179) 0.910 (0.007)
1000 2.085 (0.506) 0.943 (0.149) 0.932 (0.156) 0.912 (0.007)
1200 2.085 (0.465) 0.946 (0.141) 0.938 (0.148) 0.912 (0.007)
SAS
scenario n size (sd) TDR (sd) MCC (sd) CCR (sd)
nonlinear 800 2.011 (0.104) 0.996 (0.035) 0.997 (0.025) 0.919 (0.008)
1000 2.002 (0.045) 0.999 (0.015) 1.000 (0.011) 0.919 (0.010)
1200 2.000 (0.000) 1.000 (0.000) 1.000 (0.000) 0.919 (0.009)
riskRFE
scenario n size (sd) TDR (sd) MCC (sd) CCR (sd)
nonlinear 800 3.062 (0.949) 0.713 (0.212) 0.782 (0.171) 0.878 (0.027)
1000 2.802 (0.848) 0.772 (0.208) 0.829 (0.163) 0.883 (0.028)
1200 2.561 (0.709) 0.833 (0.192) 0.878 (0.144) 0.894 (0.021)
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APPENDIX E
Proof of Algorithm III.1 for Chapter III
According to Algorithm III.1, at iteration k (k ≥ 2), (ω(k), b(k), ξ(k)) is the op-
timal solution of the optimization problem defined in (3.2). First we prove that
(ω(k−1), b(k−1), ξ(k−1)) is a feasible solution of (3.2). It immediately follows that
h(ω(k), ξ(k)) ≤ h(ω(k−1), ξ(k−1)) due to the fact that (ω(k), b(k), ξ(k)) is the optimal
solution for (3.2). The equality holds when h(ω(k−1), ξ(k−1)) reaches the minimum.
To proceed, it is sufficient to show that the following conditions in (3.2) hold,
Ai(ω
(k−1)TXi + b
(k−1)) ≥ 1− ξ(k−1)i , i ∈ S1,
Ai(ω
(k−1)TXi + b
(k−1)) ≥ 1− ξ̃(k−1)li , i ∈ S̃
(k)





(k−1)) ≥ 1− ξ̌(k−1)li , i ∈ S̃
(k)
l , l ∈ L.
(E.1)
Note that at iteration k− 1, (ω(k−1), b(k−1), ξ(k−1)) is the solution of problem (3.2)
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(k−1)) ≥ 1− ξ(k−1)i , i ∈ S1
Ai(ω
(k−1)TXi + b
(k−1)) ≥ 1− ξ̃(k−1)li , i ∈ S̃
(k−1)
l , l ∈ L.
(E.3)
The constraints involving treatmentA in (E.1) are satisfied by (ω(k−1), b(k−1), ξ(k−1)).





(k−1)) ≥ 1− ξ̌(k−1)li , i ∈ S̃
(k−1)
l , l ∈ L. (E.4)
To prove the constraints involving y
(k−1)
li in (E.1), we consider two scenarios be-
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(k−1)) ≥ 1− ξ̌(k−1)li , i ∈ S̃
(k)
l , l ∈ L, (E.7)




S̃l stopping changing between two adjacent iterations k − 1 and k − 2.
Thus, all constraints in (E.3) have been proved to hold. This implies that all con-
straints in (3.2) hold. This completes the proof of the descending property h(ω(k), ξ(k)) <
h(ω(k−1), ξ(k−1)) when k ≥ 2. 
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APPENDIX F
Additional Simulation Results for Chapter III
If the proposed parameter tuning method based on the minimization of SSE works
well, we should see that the selected (C,λ) gives an increasing prediction accuracy
for the training dataset, a decreasing objective function, and a decreasing SSE. Our
experience from extensive simulation studies suggests that Algorithm III.1 converges
fast within typically 20 iterations. Thus, we run the algorithm over 20 iterations
to see the iteration traces. Figure F.1 illustrates the trajectories of the evaluation
criteria over the 20 iterations for the different scenarios. The values shown in each
figure are the differences of the evaluation criteria at iteration k versus k − 1, where
k = 2, . . . , 20. In Figure F.1, the increasing of the prediction accuracy, as well as the
decreasing of the objective function and SSE are evident as fully expected. Table F.1
summarizes the resulting SSE values corresponding to methods M1-M4 discussed in
Section 3.4. As is shown, M1 always gives the smallest SSE. The computation time
(in second) of methods M1-M4 is listed in Table F.2, showing that each iteration of
our method M1 takes similar running time compared with the existing OWL M4.
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Table F.1: SSE (mean (sd)) based on SS-learning with proposed tuning, SS-learning
with oracle tuning, OWL on S1, and OWL on S = S1 ∪ S2 ∪ S3.
SS-learning (tune) SS-learning (oracle) OWL in S1 OWL on S
β3 = 0.1 414.5 (32.3) 424.4 (35.5) 446.78 (42.1) 446.4 (39.9)
β3 = 0.5 428.8 (36.1) 435.1 (38.2) 508.2 (51.0) 459.7 (47.0)
β3 = 1.0 459.8 (48.2) 467.3 (50.5) 704.2 (86.4) 495.2 (65.3)
β3 = 3.0 712.2 (175.8) 743.0 (173.7) 2801.0 (571.6) 863.1 (211.4)
σ3 = 0.1 49.5 (12.2) 52.3 (12.7) 144.8 (39.0) 79.5 (37.4)
σ3 = 0.5 144.5 (17.5) 148.5 (18.7) 233.0 (40.8) 173.9 (37.1)
σ3 = 1.0 430.8 (36.4) 437.0 (37.4) 508.7 (46.5) 460.5 (44.4)
σ3 = 2.0 1529.8 (149.6) 1550.4 (105.7) 1611.3 (112.1) 1578.7 (111.0)
n1
n
= 0.04 428.8 (48.4) 436.7 (38.2) 509.8 (51.0) 461.1 (45.4)
n1
n
= 0.20 536.9 (90.8) 549.6 (93.8) 696.4 (153.4) 613.4 (115.3)
n1
n
= 0.36 623.6 (119.5) 638.0 (121.4) 771.3 (168.1) 713.9 (145.3)
n1
n
= 0.50 674.7 (149.6) 696.0 (155.9) 807.7 (180.2) 775.2 (181.2)
Table F.2: Computation time in second (mean (sd)) based on SS-learning with pro-
posed tuning, OWL on S1, and OWL on S = S1 ∪ S2 ∪ S3.
SS-learning (tune) OWL on S1 OWL on S
β3 = 0.1 0.34 (0.06) 0.08 (0.01) 0.36 (0.04)
β3 = 0.5 0.34 (0.05) 0.07 (0.01) 0.36 (0.04)
β3 = 1.0 0.34 (0.05) 0.07 (0.01) 0.36 (0.04)
β3 = 3.0 0.33 (0.05) 0.07 (0.01) 0.37 (0.04)
σ3 = 0.1 0.33 (0.05) 0.08 (0.01) 0.35 (0.04)
σ3 = 0.5 0.33 (0.05) 0.07 (0.01) 0.35 (0.03)
σ3 = 1.0 0.34 (0.05) 0.07 (0.01) 0.36 (0.04)
σ3 = 2.0 0.35 (0.06) 0.07 (0.01) 0.37 (0.04)
n1/n = 0.04 0.34 (0.06) 0.08 (0.01) 0.36 (0.04)
n1/n = 0.20 0.27 (0.05) 0.08 (0.01) 0.36 (0.04)
n1/n = 0.36 0.19 (0.03) 0.11 (0.01) 0.36 (0.04)
n1/n = 0.50 0.13 (0.02) 0.15 (0.01) 0.36 (0.04)
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Nonlinear Simulation Experiment for Chapter III
We here report another simulation experiment, which is designed with two data
sources: S1 contains high quality benefit B1 and S2 contains low quality benefit B2.
The feature vector X is generated the same way as specified in Section 3.4. Now, we
assume an observational study with treatment A = 1 allocated to subjects with prob-
ability pA = exp(ηA)/(1+exp(ηA)), where ηA = 0.4+0.5X1+0.5X3−X5−X7+0.2X9.
Logistic regression with all the main effects of X is used to estimate the propensity
score P (A | X). The underlying true decision function f is specified as f(X) =
exp(X21 ) − exp(X22 ). The observed benefit B1 is generated from a normal distri-
bution with mean µ1 = 0.01 + 0.02sin(3X4) + 3.0Af(X) and standard deviation
σ1 = 0.1, the observed benefit B2 is generated from a normal distribution with mean
µ2 = 0.1 + 0.2sin(3X4) + β2Af(X) and standard deviation σ2. Let the total sam-
ple size n = n1 + n2, where n1 = |S1| and n2 = |S2|. In order to evaluate the
performance of SS-learning under varying relevance of B1 and B2, we consider the
following scenarios: (d) β2 ∈ {0.1, 0.5, 1.0, 3.0}, σ2 = 1.0, n1 = 100, n2 = 400; (e)
β2 = 0.5, σ2 ∈ {0.1, 0.5, 1.0, 2.0}, n1 = 100, n2 = 400; (f) β2 = 0.5, σ2 = 1.0, n1 ∈
{20, 100, 180, 250}, n2 ∈ {480, 400, 320, 250}. The optimization function is solved us-
ing the RBF kernel. We set tuning parameters C ∈ {1/128, 1/64, . . . , 1/2, 1}, γ ∈
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{1/128, 1/64, . . . , 1/2, 1} and weighting parameter λ ∈ {0, 0.1, . . . , 0.9, 1.0} for pa-
rameter selection. Two different regression models are fitted for gl(X), l = 1, 2 in
parameter tuning, i) a simple linear regression with all the main effects of X, and ii)
a GAM with B-spline basis functions for X (20 basis functions for each variable).
We compare the prediction accuracy on the training and validation datasets given
by the four different methods: (M1) SS-learning with tuning according to the mini-
mization of SSE; (M2) oracle SS-learning with optimal tuning according to the highest
prediction accuracy on S1 ∪ S2; (M3) OWL with 5-fold cross-validation based tuning
of C in SVM on S1 alone; (M4) OWL with 5-fold cross-validation based tuning of C in
SVM on S1 ∪S2. Similar to the results illustrated in Section 3.4, Figure G.1 and G.2
show that the oracle SS-learning M2 always gives the highest prediction accuracy.
The M1 method gives a slightly lower prediction accuracy compared to M2. The
prediction accuracy given by M4 is constantly lower than M1 and M2. M3 usually
obtains the smallest prediction accuracy, except for the cases when the clinical rele-
vance of B2 is too small (i.e. β2 = 0.1) or when B2 has too much noise (i.e. σ2 = 2.0),
in which M4 gives the smallest prediction accuracy. It is notable that the proposed
M2 gives slightly lower prediction accuracy than M4 in the scenario of n1/n = 0.04
when parameter tuning is performed using linear regression, which is not observed
when parameter tuning is carried out by GAM. This stresses the importance of pa-
rameter tuning using the correct model that better characterizes the relationship of
the benefit value and the covariates. Table G.1 lists the selected λ2 values. Generally
speaking, λ2 increases with increasing β2, decreases with increasing σ2 and n1/n, with
exceptions when σ2 = 2.0 and n1/n = 0.50, indicating the difficulty of tuning λ2 when
B2 has too much noise and S1 has large sharing in the whole dataset.
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Table G.1: Selected weighting values λ2 (mean (sd)) based on SS-learning using the
proposed tuning method by linear regression and GAM with single low-
quality dataset.
scenario λ2 (linear) λ2 (GAM)
β2 = 0.1 0.59 (0.38) 0.55 (0.39)
β2 = 0.5 0.86 (0.27) 0.86 (0.27)
β2 = 1.0 0.94 (0.16) 0.93 (0.18)
β2 = 3.0 0.98 (0.07) 0.97 (0.08)
σ2 = 0.1 0.97 (0.09) 0.96 (0.11)
σ2 = 0.5 0.92 (0.18) 0.92 (0.19)
σ2 = 1.0 0.86 (0.25) 0.84 (0.27)
σ2 = 2.0 0.72 (0.37) 0.74 (0.35)
n1/n = 0.04 0.98 (0.07) 0.92 (0.16)
n1/n = 0.20 0.88 (0.24) 0.85 (0.27)
n1/n = 0.36 0.84 (0.25) 0.83 (0.26)
n1/n = 0.50 0.81 (0.26) 0.80 (0.25)
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Figure G.1: Comparison of prediction accuracy on the training and validation
datasets by different methods with single low-quality dataset using pa-
rameter tuning based on GAM under (a) varying β2, (b) varying σ2, (c)
varying n1/n.
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Figure G.2: Comparison of prediction accuracy on the training and validation
datasets by different methods with single low-quality dataset using pa-
rameter tuning based on linear regression under (a) varying β2, (b) vary-
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